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ABSTRACT 
Multiple sclerosis (MS) is the most common autoimmune disease of central nervous 
system (CNS) that causes chronic neurological impairment and clinical disability. 
Neuroinflammation is a major element in MS pathology and is present throughout 
the disease course contributing to clinical symptoms and irreversible neuronal 
damage. Magnetic resonance imaging (MRI) is the preferred imaging modality to 
diagnose MS. However, traditional clinical diagnosis tools are not accurate for 
comprehensive pathological assessment or short-term treatment evaluation. 
Therefore, new medical imaging methods are needed for better understanding of the 
disease process. 
The goal of this work was to evaluate novel vascular adhesion protein-1 (VAP-
1) and folate receptor (FR) targeted radiotracers and compare them with translocator 
protein 18-kDa (TSPO) targeted radiotracer for positron emission tomography (PET) 
using rat models of MS. PET studies were performed using 68Ga-DOTA-Siglec-9, 
18F-FOL, 68Ga-FOL and 11C-PBR28 radioligands to assess their ability to monitor 
neuroinflammation, disease progression and efficacy of therapies. MRI, histology, 
immunofluorescence and immunohistochemistry were performed to validate novel 
findings and to support PET data. 
VAP-1-targeting 68Ga-DOTA-Siglec-9 was able to visualize acute neuro-
inflammatory lesions ex vivo, but lacked the sensitivity to detect treatment effect and 
early MS-like lesions. FR-targeting 18F-FOL could also visualize the lesions and, 
most importantly, was able to outperform 11C-PBR28 by differentiating between 
acute and chronic lesions. 68Ga-FOL was not sensitive enough to detect treatment 
effect or lesion progression although it could visualize the MS-like lesions. 
In conclusion, FR targeting radioligands provide more specificity to PET 
imaging of MS-like lesions. FR is a potential target for in vivo imaging and 
development of therapies for MS patients. 
KEYWORDS: Multiple sclerosis, PET, neuroinflammation, folate receptor, vascular 
adhesion protein-1   
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TIIVISTELMÄ 
Multippeliskleroosi eli MS-tauti on yleisin keskushermoston autoimmunisairaus, 
joka aiheuttaa kroonisia neurologisia toimintahäiriöitä ja kliinistä toimintakyvyn 
alenemaa. Tulehdus on merkittävä osatekijä MS-taudissa ja esiintyy koko taudin 
ajan vaikuttaen kliiniseen oirekuvaan ja pysyvään hermosolujen rappeutumiseen. 
Magneettikuvaus on ensisijainen kuvantamismenetelmä MS-taudin diagnostiikassa. 
Perinteiset kliiniset diagnosointimenetelmät eivät kuitenkaan ole tarpeeksi tarkkoja 
kokonaisvaltaisen diagnoosin tai lyhyen ajan hoitovasteen arvioinnissa. Siksi uusia 
lääketieteellisiä kuvantamismenetelmiä tarvitaan ymmärtääksemme paremmin MS-
taudin kulkua.     
Tämän tutkimuksen tarkoituksena oli arvioida uusien verisuonen pinnan 
tartuntamolekyyli-1:een (VAP-1), ja folaattireseptoriin (FR) kohdentuvien radio-
aktiivisten PET merkkiaineiden käyttökelpoisuutta verrattuna 18-kDa:n translokaa-
tio proteiiniin (TSPO) kohdentuvaan merkkiaineeseen MS-taudin rottamalleissa. 
PET tutkimukset tehtiin 68Ga-DOTA-Siglec-9, 18F-FOL, 68Ga-FOL ja 11C-PBR28 
merkkiaineilla, jotta voitaisiin arvioida näiden merkkiaineiden kykyä seurata 
tulehdusreaktiota, taudin etenemistä ja lääkehoitojen vastetta. Magneettikuvausta, 
histologiaa, immunofluoresenssia ja immunohistokemiaa käytettiin uusien löydösten 
validointiin ja PET löydösten tukemiseen. 
VAP-1:een kohdentuva 68Ga-DOTA-Siglec-9 pystyi havaitsemaan akuutin vai-
heen tulehdukselliset leesiot, mutta ei lääkkeen hoitovastetta tai uusia MS-taudin 
kaltaisia leesioita. FR:iin kohdentuva 18F-FOL kykeni myös havaitsemaan leesioita 
ja ennen kaikkea onnistui erottamaan akuutin ja kroonisen vaiheen leesiot toisistaan 
paremmin kuin 11C-PBR28. Myös 68Ga-FOL havaitsi leesioita, mutta ei osoittanut 
lääkehoidon vastetta tai leesioiden etenemistä. 
Yhteenvetona voidaan todeta, että FR:iin kohdentuvat merkkiaineet tarjoavat 
lisää spesifisyyttä MS-taudin kaltaisten leesioiden PET-kuvantamiseen. FR on 
lupaava kohde sekä MS-taudin in vivo kuvantamiselle että lääkehoitojen 
kehittämiselle. 
AVAINSANAT: Multippeliskleroosi, PET, tulehdus, folaattireseptori, verisuonen 
pinnan tartuntamolekyyli-1 
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Abbreviations 
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68Ga-FOL [68Ga]gallium-labeled 1,4,7-triazacyclononane-1,4,7-triacetic acid 
conjugated folate 
ARR Annual relapse rate 
BBB  Blood-brain barrier 
BCG  Bacillus Calmette-Guérin 
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CFA Complete Freund’s adjuvant 
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CNS Central nervous system 
CSF Cerebrospinal fluid 
CT Computed tomography 
DAB 3,3'-Diaminobenzidine 
DIS Dissemination of lesions in space 
DIT Dissemination of lesions in time 
DVR Distribution volume ratio 
EC2319 Folate aminopterin drug of Endocyte  
EAE Experimental autoimmune encephalomyelitis 
EDSS Expanded disability status scale 
fDTH-EAE Focal delayed-type hypersensitivity experimental autoimmune 
encephalomyelitis 
FITC Fluorescein isothiocyanate 
fMOG-EAE Focal myelin oligodendrocyte glycoprotein experimental 
autoimmune encephalomyelitis 
FOV Field of view 
FR Folate receptor 
FR-α Folate receptor-α 
FR-β Folate receptor-β 
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Gd Gadolinium 
H&E Hematoxylin-eosin 
HEPES 2-[4-(2-hydroxyethyl)piperazin-1-yl] ethanesulfonic acid 
HEV High endothelial venule 
HPLC High-performance liquid chromatography 
iNOS Inducible nitric oxide synthase 
i.v. Intravenous(ly) 
ICAM-1 Intercellular adhesion molecule-1 
IFA Incomplete Freund’s adjuvant 
IgG Immunoglobulin G 
IFN-γ Interferon-γ 
LFB Luxol fast blue 
LJP1586 Z-3-Fluoro-2-(4-methoxybenzyl) allylamine hydrochloride 
MBP Myelin basic protein 
MRC-1 Mannose receptor C-type 1 
MRI Magnetic resonance imaging 
MS  Multiple sclerosis 
NAGM Normal appearing grey matter 
NAWM Normal appearing white matter 
NFP Neurofilament protein 
OX-42 Cluster of differentiation 11b/c 
PBR Peripheral benzodiazepine receptor 
PBS Phosphate-buffered saline 
PET Positron emission tomography 
PLP Proteolipoprotein 
PML Progressive multifocal leukoencephalopathy 
PPMS Primary progressive multiple sclerosis 
PRMS Progressive relapsive multiple sclerosis 
PSL/mm2 Photostimulated luminescence per square millimeter 
ROI Region of interest 
RRMS Relapsing-remitting multiple sclerosis 
s.c.  Subcutaneous(ly) 
Siglec-9 Sialic-acid binding immunoglobulin-like lectin 9 
SPECT Single photon emission computed tomography 
SPMS Secondary progressive multiple sclerosis 
SSAO Semicarbazide-sensitive amine oxidase 
SUV Standardized uptake value 
sVAP-1 Soluble vascular adhesion protein-1 
TAC Time-activity curve 
TB Mycobacterium tuberculosis 
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TNF-α Tumor necrosis factor-α 
TLR Toll-like receptor 
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TSE Turbo spin-echo 
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UV Ultra violet 
VAP-1 Vascular adhesion protein-1 
WM White matter 
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1 Introduction 
Multiple sclerosis (MS) is the most common chronic central nervous system (CNS) 
autoimmune disease that causes progressive disability already in young adults. MS 
has multiple identified disease components including neuroinflammation, 
demyelination and neurodegeneration, which is believed to be the pathological 
correlate for permanent clinical disability in MS (Kutzelnigg & Lassmann, 2014, 
Compston & Coles, 2008). Despite decades of research, the etiology of MS is not 
fully understood. MS is not a hereditary disease, but there are several genetic and 
environmental factors that increase the risk of developing MS. The clinical features 
of MS differ between affected individuals, the relapsing-remitting MS (RRMS) 
being the most common form of MS. In RRMS the disease is characterized by acute 
worsening of neurological symptom followed by full or partial recovery. In addition 
to RRMS, there are several progressive forms of MS. Typically, the progressive form 
of MS originates from RRMS shifting to secondary progressive MS (SPMS) or 
alternatively the MS starts as a progressive form already at the onset of the disease, 
and is diagnosed as primary progressive MS (PPMS) (Compston & Coles, 2008). 
MS continues to pose a major challenge for clinicians, as there is no specific 
diagnostic marker for MS but the diagnosis is based on clinical, magnetic resonance 
imaging (MRI) and laboratory evaluations of the patient (Sormani & Bruzzi, 2013). 
The diagnostic evaluation of MS includes gadolinium (Gd)-enhanced and T2-
weighted MRI of CNS lesions, confirmation of clinical relapses rates, and evaluation 
of clinical disability using the Expanded Disability Status Scale (EDSS) method. 
MRI is currently used as a standard tool for MS diagnosis and can detect white matter 
(WM) demyelinating lesions dominant in RRMS (Rovira & Leon, 2008). However, 
all forms of MS involve an inflammatory component, which is already observed at 
the onset of disease and becomes more prominent and diffuse during the disease 
progression affecting clinical symptoms, disease progression and lesion load 
(Ransohoff, 2012). It is clear that currently used diagnostic methods are incapable to 
evaluate disease progression or measure the inflammatory activity associated with 
MS. There is also no sensitive method for predicting the progression or observing 
therapeutic effects in MS patients (Rovira & Leon, 2008). Due to this, several MS 
patients could undergo ineffective therapy due to incomplete or false diagnosis 
Introduction 
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reducing their long-term quality of life. In addition, the mechanisms of new MS 
lesions formation are difficult to examine (Pirko & Johnson, 2008). Tissue samples 
from early lesions are challenging to obtain from living MS patients and majority of 
existing lesion samples are collected from chronic lesions in post-mortem studies. 
Hence, new non-invasive medical imaging methods and markers capable for 
evaluating early pathology in MS lesions are of high importance in the diagnostic 
field of MS. 
MS is uniquely a human disease, but experimental autoimmune 
encephalomyelitis (EAE) has been used as a fairly reliable animal model for studying 
the inflammatory component of MS (Ransohoff, 2012). From a wide range of EAE 
models, the clinically most relevant focal delayed-type hypersensitivity 
experimental autoimmune encephalomyelitis (fDTH-EAE) model can be used in 
experiments comparing lesion size, progression, and inflammatory activity (Serres 
et al., 2009). In addition, focal myelin oligodendrocyte glycoprotein experimental 
autoimmune encephalomyelitis (fMOG-EAE) is representative of acute cortical 
demyelination and widespread inflammation in the CNS simultaneously 
recapitulating many of the hallmarks of antibody-mediated inflammatory lesions in 
human MS (Serres et al., 2009). 
Vascular adhesion protein-1 (VAP-1) and folate receptor-β (FR-β) are both 
inflammation specific markers and could potentially be exploited as targets for 
imaging inflammation in MS. VAP-1 is an endothelial cell surface molecule and 
primary amine oxidase enxyme. During inflammation it is translocated from the 
intracellular storage granules to the luminal side of vessels. This controlling of the 
leukocyte extravasation is a key element in inflammatory reactions (Salmi et al., 
1993). FR’s are mainly upregulated on malignant cells in cancer and in inflammatory 
conditions, but the FR-β isoform is overexpressed on activated (not resting) 
macrophages during inflammatory conditions (Low et al., 2007) 
This thesis examines the emerging role of positron emission tomography (PET) 
imaging in the diagnostic field of chronic inflammatory CNS diseases such as MS. 
PET is non-invasive, quantitative and repetitive molecular imaging technique using 
targeted molecular probes labeled with positron-emitting radionuclides to evaluate 
rates of biochemical processes in living tissues (Kiferle et al., 2011). Molecular 
imaging of inflammation is a promising technique to identify high-risk individuals. 
However, more specific markers than the currently used glucose analogue, 
fluorodeoxyglucose 18F-FDG, are needed to assess inflammation (Autio et al., 2013). 
Novel molecular imaging targets such as FR-β and VAP-1 have been validated for 
molecular imaging of inflammation and cancer (Aalto et al., 2011, Autio, et al., 
2013). They could potentially overcome the limitations of traditionally used 
translocator protein 18-kDa (TSPO) targeted PET imaging in patients with MS (Turk 
et al, 2002, Imaizumi et al., 2007). Therefore, we investigated the utility of VAP-1 
Petri Elo 
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targeting PET radiotracer, 68Ga-DOTA-Siglec-9, and FR-targeting PET radiotracers, 
18F-FOL and 68Ga-FOL, for monitoring inflammatory activity, lesion progression 
and therapy response using animal models of MS. 
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2 Review of the literature 
2.1 Multiple sclerosis 
2.1.1 Epidemiology of MS 
MS is an autoimmune disease of CNS that causes chronic inflammation, myelin 
destruction, axonal loss and progressive neurological disability in affected 
individuals (Compston & Coles, 2008). It has been estimated that there are 
approximately 2.8 million MS patients worldwide and the number is increasing. The 
prevalence and incidence of MS is highest especially in Northern Europe, 
Scandinavia, UK, US and Canada. On the other hand, MS is rather rare in the rest of 
the world and the lowest number of MS patients are located in counties close to the 
equator line (Browne et al., 2014). This trend is reflected in part to improved 
survival, and also to better diagnosis and reporting of new of MS patients in 
developed countries, but does not completely explain these changes (Browne et al., 
2014). Environmental factors such as low exposure to sunlight, low vitamin D levels 
in serum, viral infections, high standard of living and genetic susceptibility genes 
(modifications particularly in “human leukocyte antigen” gene region) are greatly 
affecting to the increased risk of developing MS. The female-to-male sex ratio for 
MS incidence has previously been 2:1, but is currently around 4:1. Notably, this 
supports the view that hormonal factors are assumed to contribute to the formation 
and regulation of the disease course in MS (Orton et al., 2006). 
2.1.2 Diagnosis standards and criteria of MS 
The conventional clinical diagnosis standards for MS consist of clinical findings, 
new Gd-enhanced or T2 lesions detected by MRI, and evaluation of permanent 
clinical disability using EDSS (Polman et al., 2011). The clinical findings may 
include impaired vision, problems with balance, sensory disturbances, motor 
weakness, speech difficulties or fatigue depending on the location of the 
inflammatory lesion in the CNS. These symptoms are typically the first signs that 
may generate a suspicion of patient having MS, although similar symptoms are 
present in various other diseases (Compston & Coles, 2008). Therefore, these 
Petri Elo 
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clinical findings are not sufficient for definite MS diagnosis. Often these signs are 
accompanied with demyelinating plaques in the brain and/or spinal cord that can be 
demonstrated using MRI. These observations first present as a clinically isolated 
syndrome (CIS) with mono- or multifocal demyelinating lesions typically in 
brainstem or in optic nerve and a majority of these CIS patients develop clinically 
definite MS (CDMS) over time (Chan et al. 2007). As 95% patients with CDMS 
have shown to exhibit brain abnormalities, MRI is currently considered as an 
essential tool for evaluating the pathological changes that complete the diagnosis for 
MS. On the other hand, MRI has shown to be low in specificity showing variety of 
MS-like abnormalities in the brain indicating that the association of clinical disability 
and MRI findings are not optimal (Chan et al. 2007, Bakshi et al., 2008, Mollison et 
al., 2017). In addition to MRI, laboratory measurements of immunoglobulin G (IgG) 
or oligoglonal band from cerebrospinal fluid (CSF) are used to support the diagnosis 
of inflammatory lesions observed in MS and aid in the differential diagnosis (Polman 
et al., 2011). 
When the MS patient has progressed to a degree where there is permanent 
disability and deficit in neurological function, the disability can be evaluated using 
the EDSS (Kurtzke et al., 1983). It was invented and developed to assess the clinical 
severity of MS by evaluating the eight functional systems of the CNS: pyramidal, 
cerebellar, brain stem, sensory, bowel and bladder, visual, cerebral and others. The 
rating scale starts from 0 and gradually increases to 10; 0 refers to no permanent 
disability and 10 corresponds to a death due to MS (Kurtzke et al., 1983). The lower 
scale values ranging from 0 to 4 in EDSS measure impairments based on the 
neurological examination. The Mid-range values in EDSS from 4–6 mainly describe 
the walking ability of a patient, while the upper range of the scale (> EDSS 6) focuses 
on handicaps of patients with MS. EDSS is also widely used as an endpoint in clinical 
trials and as a tool to assess the effectiveness of therapeutic interventions in clinical 
trials (Meyer-Moock et al., 2014). 
The current diagnostic criteria for MS is described in the McDonald criteria 
(McDonald et al., 2001, Polman et al., 2011, Polman et al., 2005) and presented in 
Table 1. It is originally based on diagnostic criteria set out by Poser and Schumacher 
(Poser et al., 1983, Schumacher et al., 1965) but has been updated and improved 
according to scientific advancements over time. These diagnostic criteria for MS 
include clinical and paraclinical laboratory assessments, demonstration of 
dissemination of lesions in space (DIS) and dissemination of lesions in time (DIT) 
(Polman et al., 2011). Although, MR imaging is not required for the diagnosis, it is 
greatly emphasized that MRI would be used to support the clinical findings and to 
exclude any alternative diagnoses that exhibits similar symptoms compared to MS. 
Some criticisms has been pointed towards these guidelines due to their 
ineffective utilization among Asian people, because of differences in clinical 
Review of the literature 
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features. Asian-type MS patients are typically characterized with fewer Gd-
enhancing brain lesions and greater amount of Gd-enhancing spinal cord lesions 
compared to western-type MS patients. Therefore, the diagnostic criteria of MS is 
more likely to be met in an MS patient with the western-type MS (Chan et al., 2007, 
Yamasaki et al., 1996). In addition, pathological hallmarks are suggested to be more 
decisive in the diagnosis, which might improve McDonald’s criteria even further 
(Chan et al., 2007). 
Table 1.  The 2017 revised McDonald diagnostic criteria for MS according to the International 
Panel on Diagnosis of MS (Modified from Thompson et al., 2018). 
Clinical presentation Additional data needed for MS 
diagnosis 
≥2 attacks; objective clinical evidence of ≥2 
lesions 
None 
≥2 attacks; objective clinical evidence of 1 lesion 
as well as clear-cut historical evidence of a 
previous attack involving a lesion in a distinct 
anatomical location 
None 
≥2 attacks; objective clinical evidence of 1 lesion  Dissemination in space demonstrated by an 
additional clinical attack implicating a 
different CNS site or by MRI 
1 attack; objective clinical evidence of ≥2 lesions Dissemination in time demonstrated by an 
additional clinical attack or by MRI OR 
demonstration of CSF-specific oligoclonal 
bands 
 
Dissemination in space demonstrated by an 
additional clinical attack implicating a 
different CNS site or by MRI 
1 attack; objective clinical evidence of 1 lesion 
(clinically isolated syndrome) 
Dissemination in time demonstrated by an 
additional clinical attack or by MRI OR 
demonstration of CSF-specific oligoclonal 
bands 
 
2.1.2.1 Magnetic resonance imaging 
Conventional MRI can be effectively used to confirm the pathological changes 
underlying the clinical symptoms in MS. It is routinely used in the MS diagnosis 
because of its sensitivity for identifying demyelinating brain lesions, especially WM 
plaques, in T2-weighted sequences and T1-weighted contrast enhanced (e.g. Gd) 
sequences as hyperintense lesions and due to good availability of MRI scanners in 
major clinical practices. 
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Several individual MRI parameters have been shown to exhibit predictive and 
diagnostic values for disease activity and disease progression in MS. The appearance 
of new T1-weighted contrast enhanced lesion and new T2 hyperintense lesions are 
indicative of disease activity during a relapse in RRMS, during when the blood-brain 
barrier (BBB) is compromised and inflammatory reaction is intensified due to the 
influx of inflammatory cells from periphery to the CNS. In addition, brain atrophy 
can serve as a reliable marker for determining clinical progression. Increased grey 
matter athropy is believed to correlate with clinical disability in all subtypes of MS, 
whereas increased total brain atrophy and lesion volume changes combined can 
predict permanent neurological deficits (Popescu et al., 2013). 
However, there are certain limitations for MR imaging when evaluating MS 
patients in clinical setting. It is increasingly clear that MRI is insufficient for 
complete and accurate diagnosis of the disease. MRI is incapable to accurately 
evaluate disease progression, predict the subtype of MS or inflammatory activity 
(Confavreux et al., 2000). There is also no sensitive method for observing short-term 
therapy effects in MS patients. Longitudinal follow-up imaging of an individual MS 
patient could reveal patient’s response to a particular therapy or determine the 
progression of the disease, but this frequently requires several months or even years 
of time to evaluate (Fazekas et al., 2007 & Rovira & Leon, 2008, Sormani & Bruzzi, 
2013). Despite the drawbacks of conventional MRI in diagnosing MS, new 
discoveries related to non-conventional MRI-derived metrics have proven 
alternative tools to monitor the effects of new treatments and to measure multiple 
aspects of MS pathology (Rovira & Leon, 2008). These tools include the use of 
advanced techniques like proton magnetic resonance spectroscopy, magnetization 
transfer MRI and diffusion-weighted MRI, which are capable to detect more subtle 
MS related tissue abnormalities, such as, axonal damage and tissue integrity 
(Fazekas et al., 2007). 
2.1.3 Subtypes of MS 
MS is considered as a very diverse disease with multiple aspects, such as virus 
infections, genetic risk factors and environmental factors, are affecting the incidence, 
clinical fenotype, progression, disease burden and manifestations of the symptoms 
(Marrie, 2004). The clinical occurrence of MS varies greatly between the affected 
individuals and they might follow a variable patterns of clinical symptoms (Marrie, 
2004, Lublin & Reingold, 1996). Still the clinical course of the disease can be 
defined by either episodic acute periods of clinical attacks with rapid worsening in 
neurological performance, gradual progressive decline in neurological functions 
with increasing permanent disability, or combinations of both characteristics. These 
observed features have promoted the categorization of MS into four clinically 
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different subtypes (Lublin & Reingold, 1996). These clinical subtypes are presented 
in Figure 1. 
The first and the most common subtype is RRMS and 70–90 % of MS patients 
suffer from this subtype (Sumelahti et al., 2003). It is defined by disease relapses 
with full or partial recovery and periods between disease relapses that are 
characterized by a lack of disease progression (Lublin & Reingold, 1996). These 
periods are referred as remissions that typically consist of no disease activity 
(Confraveux et al., 2000), but there has been growing evidence that disease 
progression might occur even during the remission periods (Siffrin et al., 2010). The 
relapses usually last a relatively short period of time (months) and occur 
unpredictably during which the progression of the disease is very fast and the 
neurological function deteriorates rapidly (Young et al., 2006). Most of the RRMS 
patients respond to currently approved treatments for MS, which are mainly 
categorized as anti-inflammatory drugs (Frischer et al., 2009). 
RRMS will eventually develop to SPMS, where the disease progression in 
characterized as a gradual progression of the disease and permanent deficits in 
neurological function after the initial relapsing-remitting phase with approximately 
60–70% of patients transforming to SPMS within 20 years of disease onset 
(Compston & Coles 2008, Rovaris et al., 2006). It is distinguished from the RRMS 
by lack of remission periods where the progression is usually absent (Lublin & 
Reingold, 1996). The transition from RRMS to SPMS is typically assessed 
retrospectively once the patient has established a period of continuous worsening of 
neurological symptoms and permanent impairment. This time period can last up to a 
year (Rovaris et al., 2006). The most reliable pathological correlates for neurological 
disability in progressive phase of MS are considered axonal injury and 
neurodegeneration. After this transitioning, most of the currently available disease 
modifying therapies have very little impact on the disease course. In addition, the 
monitoring of pathological changes in SPMS becomes more challenging. Specific 
clinical biomarkers that could determine the onset of transition from RRMS to SPMS 
have shown little prognostic value and conventional MRI seems to poorly monitor 
MS once patient have entered to secondary progressive phase (Wingerchuk & Carter, 
2014, Lublin et al., 2014). However, increased gray matter atrophy has been claimed 
to predict clinical progression in progressive phase of MS, but this evidence remains 
controversial (Jacobsen & Farbu, 2014). Although the progression is difficult to 
determine in SPMS, the clinical symptoms show less variation than during RRMS 
and therefore are easier to predict. 
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Figure 1.  MS subtypes according to clinical course. 
PPMS is a lot rarer compared to RRMS and SPMS subtypes of MS. It occurs in 
roughly 10–15% of MS patients and consist of gradual progression in neurological 
disability already from the onset of the disease (Miller & Leary, 2007). The onset of 
the primary progressive subtype is typically later in life compared to other types of 
MS patients, but the disease usually progresses faster and appears more severe than 
SPMS (Kremenchutzky, 2003). PPMS entirely lacks remission periods or minor 
remissions might appear at very most. The pathological changes closely resemble 
the pathologies occurring is SPMS, with diffuse axonal loss, microglial activation 
and neurodegeneration occurring in gray matter and normal appearing white matter 
(NAWM) (Miller & Leary, 2007). Although there is some evidence that PPMS 
represents a distinct form of MS with significantly milder inflammatory component 
compared to other progressive forms of MS (Lassmann et al., 2012, Lublin et al., 
2014). Similar to SPMS, most of the currently available disease modifying therapies 
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show lack of efficacy in altering the disease course for PPMS with the exception of 
ocrelizumab, a monoclonal antibody selectively depleting B cells that has shown 
lower rates of clinical and MRI progression than placebo (Montalban et al., 2017). 
The rarest subtype definition according to clinical course of MS is progressive 
relapsing MS (PRMS) and it is usually the most severe in regards to clinical 
symptoms and progression (Miller & Leary, 2007). It involves gradual decline in 
neurological function already from the onset of the disease, like in other progressive 
forms of MS, but the progression is superimposed with clinical attacks or relapses. 
Patients suffering from PRMS most commonly experience a severe relapse with only 
diminutive recovery, if at all (Miller & Leary, 2007). Mitoxantrone has shown 
efficacy towards reducing progression in SPMS and PRMS (Hartung et al., 2002). 
2.1.4 Pathogenesis of MS 
The pathogenesis of MS has still remained unknown, although several complex 
mechanisms have been suggested to trigger the pathological changes occurring in 
MS. However, multiple individual components of the disease have been identified 
and these have greatly improved our understanding of MS. MS involves a strong 
inflammatory component that is present already at the onset of disease and 
subsequently becomes more prominent and diffuse affecting heavily on clinical 
symptoms, disease progression and lesion load on later stages of MS (Frohman et 
al., 2006, Ferguson et al., 1997). Demyelination, the destruction of myelin sheath 
covering axons, occurs already in early stages of MS and remains as a relevant 
pathological mechanism throughout the disease progression. It is thought that 
demyelination and inflammation in MS partially occur as a discrete events 
(Lassmann, 1999). In general, it is thought that inflammation and demyelination over 
time lead to neuronal damage, axonal loss and eventually to neurodegeneration, 
which is believed to be a pathological correlate for permanent clinical disability in 
MS (Fisniku et al., 2008). 
2.1.4.1 Neuroinflammation 
Most of the research and currently available effective therapeutic strategies are 
focused on the immunological mechanisms present in MS. Therefore, the nature of 
inflammatory response in MS is the best known aspect of the disease (Lassmann et 
al., 2007). Initially, the inflammation in the MS was considered to be a result of 
autoreactive T-cells and macrophages reacting against myelin antigens in CNS and 
causing a chronic inflammatory response leading to demyelination and further 
neuronal damage (Bruck et al., 1995). This provided a very useful concept for the 
development of first therapies, such as INF-1α and INF-1β, for MS as these therapies 
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modulated the immune response by directly altering the overall concentration of 
inflammatory cytokines to express predominantly anti-inflammatory cytokines (Th2 
cells) reducing the neuroinflammation (Kieseier, 2011). In early pathology of acute 
MS or RRMS, the composition of inflammatory infiltrates in focal plaques of WM 
lesions mainly consist of MHC I CD8+ T cells and mostly remain as CD8+ and 
macrophage dominated lesions regardless of the disease stage or activity (Lassmann 
et al., 2007). In active phases of lesions, the inflammatory response is amplified via 
BBB disruption allowing leukocyte transmigration from periphery to CNS 
parenchyma during inflammation (Alvarez et al., 2011). 
In progressive phases of MS, such as SPMS and PPMS, the nature of 
inflammation slightly shifts from active inflammatory demyelinating lesions to 
inflammatory infiltrates composed of T cells and activated microglia. These chronic 
lesions typically show slow and gradual expansion of the lesions without any 
significant demyelinating activity. At this stage, NAWM has profound expression of 
activated microglia and diffuse inflammatory processes associated with axonal 
injury and neuronal damage not just in WM, but also in cortical gray matter of the 
brain (Lassmann et al., 2007, Allen et al., 2001). The BBB is commonly restored 
with perivascular infiltrates distinguishable in blood vessels in the brain and MRI 
images display lack of Gd-enhancement, indicating that inflammation can be 
compartmentalized in the CNS behind repaired BBB (Alvarez et la,. 2011, 
Hochmeister et al., 2006). In addition, these chronic type lesions are classified to 3 
different categories according to their inflammatory cell compositions and 
demyelinating activity (Kutzelnigg et al., 2005). Chronic active lesions contain large 
amount of macrophages and microglia in a ring shape structure around the lesions 
with ongoing demyelination at these sites, whereas the core of the lesion has less of 
myelin degradation products and inflammatory cells. The second type of chronic 
lesions are considered to grow more slowly and have inactive core with some 
macrophages and microglia surrounding the core, as well as some macrophages 
located at the edge of the lesion combined with slowly occurring demyelination. On 
the other hand, the inactive lesions shown completely inactive core and non-existent 
microglial activation and macrophage recruitment throughout the lesion structure 
(Kutzelnigg et al., 2005, Kutzelnigg and Lassmann, 2014). These chronic lesions are 
most typical in progressive phases of MS, such as SPMS and PPMS, compared to 
active lesions, which are abundantly present in focal inflammatory lesions during 
RRMS. 
In addition to the absence of demyelinating lesions and microglial activation, the 
chronic inactive lesions undergo astroglial scar formation by astrocytes (Kuhlmann 
et al, 2017). Therefore, astrocytes have typically been viewed as bystander cells that 
only contribute to the glial scar formation in MS lesions once they are completely 
demyelinated, but the latest data refers to astrocytes having active role in MS lesions 
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development (Brosnan and Raine, 2013, Ponath et al., 2017). It is believed that they 
recruit lymphocytes and promote tissue damage during inflammation. In the acute 
lesions, the astrocytes tend to exhibit hypertrophic morphology, possibly due to 
disruption of astrocyte-oligodendocyte connections, where the cell soma is enlarged 
and glia limitants is retraced from the basal lamina surrounding the blood vessel in 
perivascular areas throughout the lesion. This contributes to BBB leakage and 
specific cytokine secretion enabling further recruitment of immunce cells from 
periphery to sustain the inflammation. These reactive astrocytes are present at the 
border of demyelinating lesions and are also detected in adjacent NAWM already at 
early phases of lesions development (Brosnan and Raine, 2013, Horng et al., 2017). 
However, astrocytes have also shown to confine inflammatory activity and 
contribute to tissue repair especially in the chronic demyelinated lesions. The 
formation of glial scar is considered as a barrier for other inflammatory cells and 
toxins protecting the damaged tissue from further damage. It also helps to support 
demyelinated axons and restoration of BBB function. Furthermore, neuroprotective 
toll-like receptors (TLRs) are prominently expressed in astrocytes in late stage 
chronic lesions, which is though to attenuate inflammation and support tissue repair 
mediated by TLR signaling pathways (Sofroniew, 2010, Sofroniew, 2015). Despite 
the diverse functions of astrocytes, they appear to act similarly between different 
lesions. 
However, each of these acute or chronic lesions can exhibit different lesion 
patterns that can be distinguished from each other. Pattern I lesions are dominant in 
T-cells and macrophages that are accompanied with demyelinating plaques and more 
common pattern II lesions have antibody and complement mediated inflammatory 
responses against myelin sheath. It has been demonstrated that the pattern II lesions 
are most common and are found from acute lesions. In contrast, Patterns III and IV 
are rarely observed in MS patients and are fundamentally different patterns 
compared to patterns I and II (Compston and Coles, 2008 & Lucchinetti et al., 2000). 
Pattern III lesions display characteristics of oligodendrocyte dystrophy and 
mitochondrial dysfunction leading to CNS inflammation and pattern IV lesions 
likewise show primary oligodendrocyte malfunction that rather originates from 
viral- or toxin-induced damage to myelin sheath and oligodendrocyte cells 
(Lucchinetti et al., 2000). 
2.1.4.2 Neurodegeneration 
Neurodegeneration in MS has originally believed to arise from inflammation causing 
demyelination in the axons, axonal damage, and disturbances in the remyelinating 
capacity and subsequent axonal loss. This extent of axonal injury correlated with the 
degree of inflammation and neuronal degeneration in MS brain (Trapp et al., 1998, 
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Ferguson et al., 1997). But this general view has been challenged by recent 
advancements in MS research (Frischer et al., 2009). Neuropathological studies have 
shown that profound axonal loss is occurring in NAWM, which can develop 
independently from axonal injury in demyelinating lesions (Evangelou et al., 2005, 
DeLuca et al., 2006). Furthermore, ongoing axonal injury is also observed in chronic 
inactive lesions in MS patients and demyelination associated with axonal and 
neuronal degeneration, is seen in the cortical lesions of progressive MS patients. 
Both of these pathological features were present in the absence of parenchymal 
inflammatory T- or B-lymphocytes (Bo et al., 2003). Compartmentalized 
inflammation (inflammation becomes trapped within the brain compartment) has 
been suggested as an explanation for driving disease progression and 
neurodegeneration in chronic phases of MS (Frischer et al., 2009). However, it is 
clear that axonal damage and loss can be considered as a hallmark of 
neurodegeneration and permanent disability (Compston and Coles, 2008). 
2.1.4.3 Demyelination and remyelination 
Originally it has been described by Charcot (1880) that lesions in MS are strongly 
associated with inflammation causing essential structural changes like demyelination 
and axonal damage. Although the essential components of MS have been known for 
a century, major achievements have improved our understanding about 
demyelination in MS. Currently it is believed that demyelination actually can occur 
independently of inflammation (Lassmann et al., 1999). This view is supported by 
the findings that inflammation is not restricted to demyelinating plaques as T-cell 
infiltrates and macrophages are recruited to the sites of demyelination after the initial 
steps of myelin damage (Gay et al., 1997) and active demyelination can be found 
even from patients that do not represent inflammatory cells in the active 
demyelination plaques (Prineas et al., 2001). Demyelinating lesion in MS are 
typically found in WM, but are located in cortical areas in the brain as well. This 
cortical demyelination is a characteristic feature of progressive type of disease 
(Kutzelnigg et al., 2005). Especially pattern III and IV lesions in MS demonstrate 
the discrete events of antibody-mediated demyelination and oligodendrocytes 
dystrophy related demyelination that is found in part from MS patients (Lucchinetti 
et al., 2000). In addition, evidence suggests that increased oligodendrocyte apoptosis 
in MS is not restricted to pattern III and IV lesions, but can be considered as 
important feature in all patterns of new lesion formation (Barnett & Prineas, 2004). 
For example, pattern I and II lesions show loss of oligodendrocytes at the active 
border of lesions with partial recurrence of oligodendrocytes in the inactive center 
of the lesions indicating remyelinating capacity, whereas rarer pattern III and IV 
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demyelinating lesions exhibited loss of oligodendrocytes without remyelinating 
axons (Lucchinetti et al., 2000).  
While the evidence for the driving force of oligodendrocyte apoptosis in MS 
remain controversial, profound mitochondrial disturbances in the mitochondrial 
respiratory chain has been identified as an important component in mitochondrial 
dysfunction (Mahad et al., 2008). In contrast, the number of mitochondria and their 
enzyme activity is demonstrated to be increased in demyelinated axons in inactive 
lesions. This might be interpreted as a compensatory mechanism in response to the 
initial injury in mitochondria or to the increased energy demand of demyelinated 
axons to maintain myelin status (Witte et al., 2009). Thus, the resulting energy 
deficiency due to mitochondrial injury can significantly contribute to the 
independent demyelination processes present in all MS patients (Lassmann, 2014). 
The location of demyelinating lesions can contribute to the clinical symptoms of the 
disease. Cognitive deficits have been shown to correlate with extensive hippocampal 
demyelination in MS (Geurts et al., 2007). 
Plaque formation in MS is a dynamic process highlighted by the existence of 
remyelinating lesions (Prineas & Parratt, 2012). Oligodendrocytes in recently 
demyelinated tissue exhibit a phenotype, which is known to respond to M2 polarized 
macrophages promoting new myelin formation in demyelinated axons (Miron et al., 
2013). Often times in pattern I and II lesions the recently remyelinated axons 
experience repeated rounds of demyelination until the oligodendrocytes progenitor 
cells, responsible for remyelination capacity, are exhausted from the vicinity of 
demyelinating axons. On the other hand, pattern III and IV lesions show loss of 
oligodendrocytes at the sites of demyelination and therefore are sparce of 
remyelination (Lucchinetti et al., 1999). 
2.1.5 Experimental autoimmune encephalomyelitis (EAE) 
MS is uniquely a human disease that varies with respect to symptoms, pathogenesis 
and progression of the disease between individuals. It is, therefore, extremely 
difficult to create a comprehensive animal models that would closely mimic all 
features of MS (Ransohoff, 2012). EAE is the mostly used animal model that has 
provided vast amounts of information especially on the inflammatory component 
and immune cells functions in MS, and few of the current disease-modifying 
therapies, such as natalizumab, glatiramer acetate and mitoxantrone have been 
developed originally in EAE (Mix et al., 2010). 
It is noteworthy that the clinical course of the EAE is affected by several 
individual factors like antigen, administration route and animal species (Gold et al., 
2006). For example, immunization with myelin oligodendrocyte glycoprotein 
(MOG) creates acute EAE in C57BL mice presenting no options to evaluate relapses, 
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whereas immunization with myelin basic protein (MBP) or proteolipoprotein (PLP) 
results in chronic relapsing-remitting active EAE when induced in Swiss James 
Lambert mice (Mix et al., 2010). Active models of EAE require subsequent 
activation of immune response via injection of pertussis toxin, Complete Freund’s 
Adjuvant (CFA) or Incomplete Freund’s Adjuvant (IFA). Usually lesions in EAE 
are created in random and variable fashion that are located throughout the brain and 
spinal cord leading to severe inflammation in the CNS, but in focal delayed-type 
hypersensitivity (fDTH) model of EAE in Lewis rat the individual lesion is created 
focally (Anthony et al., 1998). It first resembles the characteristics of acute EAE and 
then progresses to chronic progressive lesion that closely mimics the lesions 
observed in progressive MS. Regarding lesion pathology, DTH lesion includes BBB 
breakdown, demyelination, T cell and macrophage infiltration at the acute phase of 
the disease and widespread microglial activation with demyelination and recruitment 
of peripheral immune cells at the chronic phase of the disease (Airas et al., 2015 and 
Serres et al., 2009). Therefore, the clinically more relevant fDTH-EAE can be used 
to compare lesion size, inflammatory activity and progression (to some extent) 
without the interference of newly formed neighboring lesions (Anthony et al., 1998 
and Serres et al., 2009). The different features of common EAE models are displayed 
in Table 2. 
The nature of the inflammatory response and the lesion progression in EAE 
differs to some extent from MS. Whereas patients with MS are commonly 
characterized with CD8+ T cell and macrophage dominated inflammatory lesions, 
the inflammatory response in EAE is CD4+ T cell dominated (Sriram and Steiner, 
2005, Ransohoff, 2006). Secondly, inflammation is a primary event in EAE causing 
CD4+ T cells and CD8+ T cells to target CNS myelin antigens, such as MBP, PLP 
and MOG followed by demyelination events. In MS the inflammation process is 
believed to be induced as a consequence of damage to oligodendrocytes or microglia, 
respectively, leading first to persistently demyelinating axons and subsequent 
inflammatory reaction in attempt to repair the damaged myelin and axons (Prineas 
& Parratt, 2012). 
EAE models are lacking the ongoing myelin destruction and function 
deterioration observed in MS. Second, studying chronic remyelination cannot be 
investigated in EAE and the lesions in EAE are mainly occurring in WM. Thirdly, 
EAE models are poor in studying B cell activity in CNS inflammatory process, with 
the exception of fMOG-EAE that causes antibody-mediated acute inflammation with 
cortical demyelination (Merkler et al., 2006 and Hauser et al., 2008). These features 
of EAE are still limiting the capability of preclinical studies in discovering the 
pathological mechanism driving the permanent neuronal dysfunction and clinical 
disability typical for MS patients. 
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2.1.6 Currently available disease-modifying treatments 
Although there is still no curative treatment for MS, most of the currently approved 
disease-modifying treatments have shown efficacy in reducing inflammation, 
formation of new T2 or T1 Gd-enhancing lesions, annual relapse rate (ARR) and 
slow disease progression (Corboy et al., 2003, Thorkildsen et al., 2016). As majority 
of patients have the RRMS subtype, the therapies are primarily indicated for treating 
clinical conditions often preceeding CDMS, such as radiologically isolated 
syndrome and CIS that eventually tend to develop to RRMS (Niino, 2012). There is 
evidence that these available immunotherapies appear to have maximum efficacy 
when initiated early in the course of the disease also improving the long term 
disability prognosis (Freedman et al., 2013). However, the neurodegenerative 
component of MS cannot be effectively treated with any current medications. In 
contrast to therapy options for RRMS, there is currently no effective treatments for 
reducing the clinical disability in progressive forms of MS (Leary & Thompson, 
2005), with the exception of an anti-CD20 therapy, which has an impact on lowering 
the clinical disease progression rate in patients with PPMS (Montalban et al., 2017). 
Although partially efficacious in PPMS, the anti-CD20 therapies pose an increased 
risk of secondary antibody deficiency that might lead to significant complications 
like serious infections associated with hypogammaglobulinemia (Tallantyre et al., 
2018). All approved therapies for MS are displayed in a Table 3. 
There has been over 20 years of experience in the use of therapies that are able 
to alter the disease course in RRMS (Hauser et al., 2013, Thorkildsen et al., 2016). 
Currently the focus of the development of new therapies has changed towards not 
only reducing inflammatory activity and ARRs in MS, but halting clinical disability 
and preventing new disease activity in all subtypes of MS (Havrdova et al., 2010). 
Up to date, several first-line treatments have been developed including interferon 
beta, teriflunomide, glatiramer acetate, dimethyl fumarate, diroximel fumarate and 
siponimod (Thorkildsen et al., 2016, FDA news release, 2019). In general, the first-
line medications have shown efficacy in reducing the ARR by about 30%, reducing 
the progression of disability in RRMS and disease activity measured with MRI, 
while the most common side effects present transitory flu-like symptoms like fever, 
chills, headache and back pain (Ebers, et al., 1998, Comi et al., 2001). 
For second-line medications, the treatment effect is more drastic. The effect in 
reducing the occurrence of commonly used primary endpoints in clinical MS trials 
is normally 25–50% compared to first-line treatments. However, these medications 
may be associated with grater risks of developing severe CNS complications, such 
as progressive multifocal leukoencephalopathy (PML), compared to first-line 
therapies (Thorkildsen et al., 2016). These second-line therapies for example include 
fingolimod, natalizumab, alemtuzumab, cladribine, mitoxantrone and ocrelizumab 
(Thorkildsen et al., 2016, FDA news release, 2019, Montalban et al., 2017). 
 
Table 2.  Characteristics of commonly used EAE animal models in preclinical research of MS. 
 
EAE models 
 
induction 
 
activation 
development  
of symptoms 
 
lesion pathology 
 
intended use 
clinical 
symptoms 
Active EAE with 
whole brain 
immunization, 1) 
Repeated injections (i.m.) 
of brain emulsions and 
extracts in water-oil 
emulsion 
— days Sings of meningitis, 
demyelination 
virus-induced 
paralysis 
local or 
systemic 
paralyses, 
death 
Active EAE with 
whole myelin, 2) 
With MBP/PLP emulsified 
in CFA 
— 10-21 days no/little demyelination, 
CD4+cells, disseminated acute 
lesions 
inflammation 
and relapses in 
EAE 
weight loss, leg 
paralysis, 
tremor 
Active EAE with 
MBP-peptides or 
MBP-specific 
lymph node cells, 
3) 
Injection (s.c.) of MBP-
peptides or lymph node 
cells and TB 
Injection 
(i.p.) of 
pertussis 
toxins 
11-18 days no/little demyelination, 
CD4+cells, disseminated acute 
lesions 
inflammation, 
relapses and 
therapies in 
EAE 
loss of righting 
reflex, limb 
paralysis 
Active EAE with 
MOG, 4) 
Immunized with MOG or 
MOG-peptides in CFA 
supplemented with TB 
Injection (i.v.) 
of pertussis 
toxins 
10-25 days widespread demyelination, 
encephalitogenic T cells, 
(CD3+), macrophages and 
astrocytes 
development of 
immunotherapi
es 
loss of righting 
reflex, limb 
paralysis 
AT-EAE with Th17 
cells or lymph node 
cells, 5) 
Injection of myelin-
reactive CD4+ or Th17 
cells 
— 14-18 days minimal demyelination, spinal 
cord lesions, widespread 
inflammation, encephalitogenic 
T cells and B cells 
primarily 
evaluation of 
pathology in 
EAE and in MS 
limb paralysis, 
loss of 
coordinated 
movement 
AT-EAE with 
myelin targeted 
CD8+ cells, 6) 
Injection of myelin-
reactive CD8+ cells 
— 3-14 days more lesions in the brain, 
milder inflammation, CD8+ 
cells, lymphocytes and 
macrophages 
pathology in 
EAE and in MS 
ataxia, weight 
loss, paralysis, 
death 
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Table 2.  Continued 
 
EAE models 
 
induction 
 
activation 
development of 
symptoms 
 
lesion pathology 
 
intended use 
clinical 
symptoms 
Chronic 
progressive EAE 
with pertussigen, 7) 
mouse spinal cord in CFA 
containing TB 
pertussi-gen 11 days –  
3 months 
T lymphocytes, macrophages, 
CD4+ dominated lesions, 
mononuclear cells 
Chronic CNS 
inflammation 
evaluation  
weight loss, 
limb paralysis, 
tremor 
Transgenic EAE, 8) Transgenic modification ( 
for example IL-12, TNF-α, 
INF-γ) 
— 1-6 months Inflammatory demyelinating 
lesions in the CNS, neutrophilic 
granulocytes, macrophages 
and T lymphocytes 
Individual 
cytokines in 
EAE 
pathogenesis 
tremor, ataxia, 
epilepsy 
Focal MOG-EAE, 
9) 
Immunization (s.c.) with 
MOG-peptides 
cytokines 
(corpus 
callosum) 
1-18 days B cells, complement activation, 
microglia and macrophages, T 
lymphocytes 
B cells in CNS 
inflammation, 
relapses 
loss of weight, 
epilepsy, 
incoherence 
Focal DTH-EAE, 
10) 
BCG injection in striatum Injection of 
CFA with TB 
11 days –      
6 months 
microglia and macrophages, T 
lymphocytes, CD4+ dominated 
lesions 
acute & chronic 
CNS 
inflammation 
mild 
incoherence 
and weight loss 
From studies: 1) = Freund et al 1947, 2) = Laatsch et al 1962, 3) = Wekerle et al 1994, 4) = Genain et al 1995, 5) = Paterson et al 1960, 6) = Huseby et 
al 2001, 7) = Munoz et al 1984, 8) = Goverman et al 1993, 9) = Merkler et al 2006 and 10) = Serres et al 2009.
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Table 3.  Currently available disease-modifying therapies for MS. Modified from Thorkildsen et al 
2016 and supplemented from fda.gov (news release, 2019). 
Therapy 
(administration) 
 
Suggested mode of action 
Approved 
indication 
Interferon β 1-a/b 
(i.m. or s.c.) 
Inhibition of T-lymphocyte proliferation CIS, RRMS & 
active SPMS 
Glatiramer acetate 
(s.c.) 
Promotes Th2 and Treg differentiation for anti-
inflammatory effect 
CIS, RRMS & 
active SPMS 
Teriflunomide  
(p.o.) 
Inhibition of de novo pyrimidine synthesis leading 
to reduced number of circulating lymphocytes 
CIS, RRMS & 
active SPMS 
Dimethyl fumarate 
(p.o.) 
Anti-inflammatory effects mediated through NRF2 
transcriptional pathway 
CIS, RRMS & 
active SPMS 
Diroximel fumarate 
(p.o.) 
Anti-inflammatory effects mediated through  
NRF2 transcriptional pathway with improved 
gastrointestinal tolerability 
CIS, RRMS & 
active SPMS 
Fingolimod  
(p.o.) 
S1PR mediated inhibition of autoreactive 
lymphocyte transmigration from the lymph nodes 
to the CNS. 
CIS, RRMS & 
active SPMS 
Siponimod  
(p.o.) 
Similar to Fingolimod, but more selective 
modulation of S1PR, modulates S1PR1 and 
S1PR5 subtypes 
CIS, RRMS & 
active SPMS 
Natalizumab  
(i.v.) 
Monoclonal anti-VLA-4 antibody against α4-
integrin, inhibiting the migration of inflammatory 
cells into the CNS. 
CIS, RRMS & 
active SPMS 
(monotherapy) 
Alemtuzumab  
(i.v.) 
Monoclonal anti-CD52 antibody, antibody 
dependent cellular cytolysis and complement-
mediated lysis causing depletion and repopulation 
of lymphocytes 
RRMS 
Mitoxantrone  
(i.v.) 
Interacts with nuclear DNA and targets 
proliferating immune cells, inducing apoptosis of 
T- and B lymphocytes and macrophages. 
RRMS, SPMS & 
PRMS 
Cladribine  
(p.o.) 
Deoxyadenosine analog phosphorylation resulting 
in preferential and sustained reduction of 
peripheral T and B lymphocytes 
CIS, RRMS & 
active SPMS 
Ocrelizumab  
(i.v.) 
Monoclonal anti-CD20 antibody, selective depletion 
of CD20-expressing B cells 
CIS, RRMS, 
SPMS & PPMS 
 
 
Review of the literature 
 31 
2.2 Positron emission tomography 
PET imaging is a promising technique to identify disease processes in living patients. 
It offers a valuable approach to diagnosis, therapy planning and in vivo monitoring 
and it can especially be exploited for imaging cancer and inflammation (Autio et al., 
2013). Although MRI has been considered as a gold standard for diagnosing and 
evaluating the brain abnormalities related to MS, PET imaging has also a valuable 
potential to explore relevant aspects of neuroinflammation, neurodegeneration and 
visualize extralesional pathological processes that are present in progressive forms 
of MS (Airas et al., 2015, Barkhof, 2002). In addition, Gd-enhanced and T2-
weighted MRI at 6 to 12 months after an effective therapy initiation is required to 
demonstrate the reduction in pathological hallmarks of MS (Miller et al., 1996). This 
efficacy could optimally be observed in MS patients after weeks with PET imaging. 
2.2.1 Principles of PET imaging 
PET imaging is non-invasive, three dimensional (3D), quantitative and repetitive 
molecular imaging technique using targeted probes labeled with positron-emitting 
radionuclides to visualize and measure rates of biochemical processes in tissues of 
living subjects (Kiferle et al., 2011). In a PET radioligand, these probes are usually 
chemically incorporated with a short-lived radionuclide such as 11C, 13N, 15O, 18F and 
68Ga, which will eventually cause (γ) radiation at the target site detectable with PET 
camera. Over time, the radioligand accumulates at this target site and can be 
quantified as a function of time within a region of interest (ROI). 
In more detail, the radionuclides used in PET imaging are radioactive isotopes 
that undergo a radioactive beta plus (β+) decay, where proton is converted into a 
neutron and at the same time the proton is emitting a positron and neutrino. These 
emitted protons travel in a tissue releasing their kinetic energy until the proton 
collides with an electron. This annihilation of proton and electron will result in an 
emission of two gamma γ-photons, which will travel roughly in opposite direction 
(180, 25°) with 511 keV energy. This event is detected by scintillation detector 
crystals located in a rim shaped structure in a PET camera around the imaged object 
(Cherry et al., 1997, Turkington et al., 2001). The detectors trace the location of the 
initial annihilation site along the line of response. It is noteworthy that most 
annihilation events are rejected, because both annihilated photons of a single event 
may not hit the detector. As only linear annihilation events are included in the PET 
image production, nonlinearity of annihilation, among crystal size and positron range 
are significantly restricting the spatial resolution of a PET image (Ching et al., 2012). 
Finally, photomultiplier tubes are used to improve the acquired signals and image 
reconstruction algorithms form the final image for analysis. 
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Typically PET data is acquired either from static or dynamic images. In static 
PET imaging, the image data is collected over a single time frame to visualize the 
radioligand distribution in an imaged object. These static imaging protocols are 
beneficial as they offer clinical applicability, where the relative tracer uptake is of 
interest (e.g. cancer diagnosis). However, static imaging protocols may cause bias if 
only a single image is considered to represent the overall tracer metabolism (Muzi 
et al., 2012). On the other hand, dynamic PET imaging utilizes the time-activity 
curves (TAC’s) that represent the amount of radioactivity in each pixel as a function 
of time during the time course of the imaging. Therefore, dynamic PET imaging 
provides better assessment tools on the tracer uptake, kinetics and retention than 
static PET imaging and is often used as a PET data acquisition method during new 
PET radioligand studies (Kiessling et al., 2017, Muzi et al., 2012). 
2.2.2 PET radioligands in the imaging of MS patients 
PET imaging studies of MS have utilized the neuroinflammatory reactions generally 
involved in neurodegenerative and neoplastic brain disorders (Chauveau et al., 
2008). CNS is characterized as an immunoprivileged site with the presence of BBB 
and reduced immunosurveillance due to lack of normal lymphatic drainage. 
Therefore, the cellular response in neuroinflammation alters from the immune 
response occurring in periphery (Bailey et al., 2006). Neuroinflammation involves 
the activation of cells such as astrocytes, microglia and peripheral infiltrated 
macrophages, which all express elevated levels of TSPO formerly referred to as the 
peripheral benzodiazepine receptor (PBR). TSPO is a membrane protein in an outer 
mitochondrial membrane that is expressed in various cell and tissues types 
throughout the body, but the basal expression of TSPO under normal conditions in 
CNS is very low. Hence, TSPO is considered as a marker of inflammation in the 
brain (Harberts et al., 2012). Majority of the PET radioligans are consequently 
targeting TSPO and radiolabeling of TSPO ligands have allowed the imaging of 
TSPO expression in neuroinflammatory conditions, and established the concept of 
PET imaging in diagnosing MS (Schweitzer et al., 2010, Luus et al., 2010). 11C-
labeled tracer 11C-(R)-PK11195 (11C-N-methyl-N-[1-methylpropyl]-1-[2-
chlorophenyl]-isoquinoline-3 carboxamide, ([11C]PK11195) was the first tracer to be 
consistently used in PET imaging studies, because of its usefulness in animals and 
clinical studies of neuroinflammation. Despite the popularity, it possesses numerous 
limitations including low binding affinity, high lipophilicity, poor signal-to-noise 
ratio, lack of selectivity and capability to visualize subtle levels of TSPO expression 
(Dickens et al., 2014, Ching et al., 2012). In addition to [11C]PK11195, [11C]Ro5-
486 is also considered to belong to first generation TSPO radioligands. However, the 
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binding affinity of [11C]Ro5-4864 is both temperature- and species-dependent 
drastically limiting its use in further human studies (Farges et al., 1994). 
The development of second generation TSPO radioligands has attempted to 
solve these issues related to first generation TSPO radioligands with various stages 
of success (Schweitzer et al., 2010). In general, the second generation TSPO 
radioligands exhibit improved specificity, affinity, lower lipophilicity, lower 
nonspecific binding and metabolism compared to e.g. [11C]PK11195 (Imaizumi et 
al., 2007). These TSPO ligands have typically constructed from other structural 
classes like acetamides, vinyl alkaloids or pyrazolopyrimidines (Alam et al., 2017). 
The most important first, second and new generation TSPO radioligands in human 
studies have been summarized in Figure 2. 
 
Figure 2.  First and second generation TSPO radioligands in clinical studies. (Modified from Alam 
et al., 2017). 
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2.3 New imaging targets and radioligands for PET 
imaging of MS 
Despite the recent developments, TSPO targeting radioligands are not microglia or 
macrophage specific markers by definition, which has given rise to the development 
of new generation radioligands that use alternative targets for imaging microglia and 
macrophages (Lavisse et al., 2012). The goal with the new PET imaging agents is 
either to target microglia or macrophage-specific markers, detect the independently 
occurring neurodegeneration or to trace the source of progressive disability in MS 
(Rissanen et al., 2013, De Paula Faria et al., 2014). Therefore, several novel targets 
for imaging MS have been identified and they are represented in Table 4.  
2.3.1 Vascular adhesion protein -1 
An example of an alternative molecular target for PET imaging of MS or EAE is 
VAP-1. Each of the MS subtypes, RRMS, SPMS, PPMS, RPMS, comprises of 
inflammation that is present already at the onset and is more heavily involved on 
later stages as the disease progresses. In all cases, residential immune cells in the 
CNS are insufficient to completely regulate the pathogen defense (Siffrin et al., 
2010). Therefore, amplification of immune response from the periphery is 
considered as substantial in pathogenesis of MS (Airas et al., 2006). This immune 
cell recruitment requires interaction between leukocyte ligands and its receptors on 
endothelial cell wall mediated by several adhesion molecules from which VAP-1 
plays a crucial role in this process (Carlos et al., 1994). 
VAP-1 is a 170-kD endothelial cell surface molecule with dual function: both 
adhesive and enzymatic properties. It is mainly responsible for controlling the 
transmigration of leukocytes to the sites of inflammation and conversion of primary 
amines into corresponding aldehydes. Under normal condition, VAP-1 is stored in 
intracellular storage granules located in the vessel wall. Although during 
inflammation, VAP-1 is rapidly upregulated by the endothelial cells and it is 
translocated from the intracellular granules to the luminal surface of the endothelium 
(Salmi et al, 1993, Castillo et al., 1998). 
Leukocyte transmigration is also mitigated by BBB breakdown, where the 
leukocytes can passively migrate to CNS parenchyma without active transportation 
by adhesion molecules (Alvarez et al., 2011). One might suspect that in MS the BBB 
remains active for adhesion molecules like VAP-1 once the BBB has initially been 
compromised during a relapse in RRMS. Based on this assumption, VAP-1 targeted 
PET radioligands could constitute as a promising approach for PET imaging of MS. 
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Table 4.  PET radioligands applied in MS patients or animal models of MS (Modified from De 
Paula Faria et al., 2014 and supplemented from Auvity et al., 2020). 
Target  MS characteristic PET tracer 
Application of PET 
imaging 
TSPO Neuroinflammation [11C]PK11195 Clinical 
TSPO Neuroinflammation [11C]PBR28 Clinical 
TSPO Neuroinflammation [11C]vinpocetine Clinical 
TSPO Neuroinflammation [18F]FEDAA1106 Preclinical 
TSPO Neuroinflammation [11C]DAC Preclinical 
TSPO Neuroinflammation [18F]DTPA714 Preclinical 
TSPO Neuroinflammation [18F]PBR111 Preclinical 
Glucose metabolism Neuroinflammation and 
neurodegeneration 
[18F]FDG Clinical 
A2A receptors lymphocytes and 
macrophages 
[11C]TMSX Clinical 
A1 receptors Downregulation in MS [11C]DPCPX Preclinical 
A1 receptors Downregulation in MS [11C]MPDX Preclinical 
Choline metabolism De- and remyelination [11C]Choline Clinical 
Choline metabolism De- and remyelination [11C]BMB1 Preclinical 
Myelin De- and remyelination [11C]CIC Preclinical 
Myelin De- and remyelination [11C]MeDAS Preclinical 
Myelin De- and remyelination [11C]PIB Clinical 
Cholinergic neurons Neurodegeneration [11C]MP4A Clinical 
Amylod-β deposits Damaged white matter [18F]Florbetaben Clinical 
 
2.3.1.1 68Ga-DOTA-Siglec-9 
The translocation of VAP-1 to the luminal side of blood vessels is a key element 
in controlling leukocyte trafficking during inflammatory conditions (Salmi et al, 
1993). This process can be utilized in in vivo PET imaging. It has also been 
discovered that sialic-acid binding immunoglobulin-like lectin 9 (Siglec-9) is a 
leukocyte ligand of VAP-1 and 68Ga-labelled Siglec-9 motif facilitates in vivo 
imaging of inflammation. Gallium-68-labelled 1,4,7,10-tetraazacyclododecane-
N,N′,N′′,N′′′-tetraacetic acid conjugated sialic acid-binding immunoglobulin-like 
lectin 9 (68Ga-DOTA-Siglec-9) has successfully been used for imaging of peri-
implant infections in rats, tumor melanoma models, animal models of 
atherosclerosis and inflammation (Aalto et al., 2011, Ahtinen et al., 2014, Siitonen 
et al., 2019, Silvola et al., 2016). In addition, the inhibition of VAP-1 activity in 
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non-clinical studies has shown to reduce EAE symptoms in mice once the disease 
has progressed to a relapse phase (O’Rourke et al., 2007). Therefore, 68Ga-DOTA-
Siglec-9 could be considered as a promising approach for PET imaging of 
neuroinflammation related conditions such as MS. 
2.3.2 Folate receptor –β 
Folic acid (folate) is considered as a necessary ingredient for normal cell survival, 
proliferation and function (Hilgenbrink & Low, 2005). In healthy cells, the folate is 
usually acquired via either a reduced folate carrier and/or the proton-coupled folate 
transporter (Sirotnak & Tolner, 1999, Qiu et al., 2006). Nevertheless, the remaining 
folate uptake system is the high-affinity cell surface folate receptor (FR), a glycosyl 
phosphatidyl inositol–anchored glycoprotein (38–45 kDa) that binds preferentially 
to folic acid with approximately 1000-fold higher affinity for folate than other folate 
transportation pathways. This FR is largely upregulated on malignant cells in cancer, 
atherosclerosis and in inflammatory conditions (Low et al., 2007). Generally, there 
are four different isoforms (folate receptor-α, (FR-α), -β, -γ and –δ) of FRs 
recognized, which two of them are specific for pathological conditions. Whereas, 
FR-α isoform is upregulated primarily on tumor cells that require excessive amounts 
of folate for abnormal cell proliferation (Elnakat & Rathnam, 2004), the FR-β is 
overexpressed on activated (not resting) macrophages during inflammation 
conditions, such as in rheumatoid arthritis, Crohn’s disease, atherosclerosis, 
inflammatory osteoarthritis and in animal models of EAE, and therefore constitutes 
as an excellent marker for inflammatory conditions (Low & Anthony, 2004, Turk et 
al., 2002). In contrast to previous FR isoforms, FR −γ and –δ isoforms are detected 
in normal and malignant hematopoietic cells and are not consequently considered as 
a promising targets for therapeutic interventions or imaging agents (Elnakat & 
Rathnam, 2004). 
However, FR-α and FR-β have been targets for the development of folate-based 
imaging and therapeutic agents because the concept of folate-conjugation provides 
multiple advantages compared to conventional agents including relatively easy and 
straight-forward conjugation process, finite availability of FR in healthy tissues, very 
high affinity (KD = 10 nM) for FR-α and FR-β isoforms and consequently low 
toxicity (Low et al., 2007). 
Although FR-β expression is relatively little studied in MS or EAE, it would 
provide a potential target for diagnosing MS, because macrophages and microglia 
are known to be fundamental for MS and EAE pathogenesis. Growing amount of 
research supports the view of functionally different polarization phenotypes in 
inflammatory reactions in MS or EAE (Janssen et al., 2018, Lassmann et al., 2007, 
Bogie et al., 2014). In these conditions, microglia and macrophages are considered 
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to be polarized into proinflammatory M1 or immunomodulatory M2 dominant 
polarization patterns where M1 proinflammatory alterations have developed to 
induce inflammatory reactions, pathogen-defense and propagate disease process. 
M2 phenotype is characterized by immunoregulatory functions, tissue remodeling, 
remyelination, debrief cleaning or inducing and maintaining recovery from chronic 
inflammation (Miron et al., 2013, Sica & Mantovani, 2012). Based on the 
expression patterns of FR-β on either M1 or M2 polarized macrophage phenotypes, 
FR-β-targeted folate-conjugated in vivo imaging agents could further facilitate in 
capturing the heterogeneity of dynamic activation patterns occurring in 
neuroinflammation. 
2.3.2.1 Al18F-NOTA-Folate 
Various folate-targeted in vivo PET imaging compounds have shown promise in 
imaging activated macrophages that are relevant in the pathogenesis and immune 
response in several inflammatory conditions (Hilgenbrink & Low, 2005, Low et al., 
2007). Especially, aluminum [18F]fluoride-labeled 1,4,7-triazacyclononane-1,4,7-
triacetic acid conjugated folate ([18F]AlF-NOTA-Folate, 18F-FOL) has recently been 
successfully studied as a PET imaging agent for targeting FRs in tumor xenografts 
and inflammatory atherosclerotic lesions (Chen et al., 2016, Silvola et al., 2018). It 
has shown to pose improved radiopharmaceutical properties over 99mTc-EC20, a 
clinically established folate-targeted single photon emission computed tomography 
(SPECT) imaging agent, providing a viable alternative tool for imaging FR-positive 
conditions (Chen et al., 2016). In addition, there is evidence that FR-β-mediated 
interventions attenuate symptoms and histopathological changes in EAE (Lu et al., 
2014). However, it still remains to be evaluated whether 18F-FOL would present a 
promising new tool for the in vivo imaging of neuroinflammation in rats with EAE 
or humans with MS. 
2.3.2.2 68Ga-NOTA-Folate 
The rapid development of PET imaging is partially restricted by the requirement of 
onsite cyclotron for radioligand production, which is relevant especially with 18-
fluorine labeled radioligands (McBride et al., 2009). Hence cyclotron independent 
production of radiotracers with 68Ga-labelling, which is performed with 68Ge/68Ga 
generator, would be a welcomed approach for imaging folate-receptor positive 
conditions. As [68Ga]gallium-labeled 1,4,7-triazacyclononane-1,4,7-triacetic acid 
conjugated folate (68Ga-NOTA-Folate, 68Ga-FOL) has previously demonstrated the 
ability to detect folate-receptor positive tumors in tumor xenograft mice (Aljammaz 
et al., 2014), it would be a tempting approach to evaluate the utility of 68Ga-FOL in 
Petri Elo 
 38
visualizing inflammatory activity, disease progression and monitoring FR-β targeted 
therapy effects in EAE rat models and potentially in clinical trials in patients with 
MS in the future. 
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3 Aims 
The overall aims of this study were to evaluate novel molecular imaging methods 
for monitoring neuroinflammation, disease progression and efficacy of therapy using 
animal models of MS. The specific aims for each sub study is described below: 
1. To investigate the role of VAP-1 and feasibility of VAP-1-targeted 68Ga-
DOTA-Siglec-9 PET in monitoring neuroinflammation and efficacy of 
treatment in EAE rats. 
2. To evaluate the ability of a novel FR-targeted PET radioligand, 18F-FOL, 
to detect activated macrophages/microglia in a rat EAE model and to 
compare it with TSPO radioligand for monitoring neuroinflammation 
and progression of the disease. 
3. To study efficacy of folate aminopterin treatment on EAE rats and 
feasibility of FR-targeted 68Ga-FOL PET radioligand to detect 
neuroinflammation. 
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4 Materials and methods 
4.1 EAE rat models 
There are several types of EAE models that vary in respect to nature, severity and 
duration of the inflammation and method of establishment. In this work, I have 
focused only on two specific clinically relevant EAE models that enable the 
evaluation of individual lesion formation, ascertainment of BBB integrity during its 
disease course, easier measurement of therapy efficacy on individual lesion and 
monitoring of lesion development by in vivo PET imaging. Animal experiments that 
were performed related to this work were approved by the national Animal 
Experiment Board of Finland and the Regional State Administrative Agency for 
Southern Finland (license numbers: ESAVI/3046/04.10.07/2014 and 
ESAVI/2979/2018) and were conducted according to the relevant European Union 
directive. 
4.1.1 Focal delayed-type hypersensitivity EAE (fDTH-EAE) 
FDTH-EAE rat model was established in two phases. The disease was induced with 
the intrastriatal injection of heat-killed Bacillus Calmette-Guérin (BCG) that created 
the initial and transitory inflammatory response. Subsequently the BCG accrual was 
activated with peripheral injection of CFA supplemented with Mycobacterium 
tuberculosis (TB) to complete the CD4+ cell and macrophage-mediated immune 
response against the BCG site. 
When inducing the fDTH-EAE, the rats were first anesthetized with isoflurane 
anesthetic mixed with air (induction: 4–5% isoflurane and 500 mL-700 mL/min air, 
maintenance: 2.0–2.5% isoflurane and 400 mL-500 mL/min air) and set on a heating 
pad to maintain rat body temperature during the procedure. The rats were 
administered with subcutaneous (s.c.) injection of 100 µL analgesic (buprenorphine, 
0.05 mg/kg/day, Temgesic, Indivior, Berkshire, UK) once just before the operation 
and 24 h after the operation and local anesthetic (Emla, AstaZeneca, Södertälje, 
Sweden) was applied in the ears of rat to attenuate the pain caused from fixing the 
head into the stereotactic frame. Then the rat’s head was placed on a fixed coordinate 
system for stereotactic surgery and a one centimeter incision was made to the scalp 
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to enable the drilling of a 1.0 mm diameter hole 1.0 mm anterior and 3.0 mm lateral 
from the bregma at the depth of 4.0 mm from the surface of the cortex with a special 
dentist drill. The injection of two µL BCG (BCG, a kind gift from Professor Daniel 
Anthony, Department of Pharmacology, University of Oxford, UK) suspension 
(5×105 organisms in 1 μL of saline) was then performed with a Hamilton micro-
syringe (Hamilton Bonaduz AG, Bonaduz, Switzerland) over time period of 10 
minutes. After the injection, the wound was closed with stiches and disinfected with 
alcohol. The rats were allowed to recover on the heating pad until recovered from 
anesthesia. 
Four weeks from the BCG induction into the striatum, the lesion was activated 
with intradermal injection of 100 µL of heat-killed TB (H37Ra, InvivoGen, San 
Diego, CA, USA) in an emulsion of CFA (CFA)/saline emulsion (100 μL, Sigma 
Aldrich, St. Louis, MO, USA) into the hind limbs of the rat. Before the procedure, 
the rats were anesthetized with mixture of isoflurane and air as with stereotactic 
operation and set on a heated cradle for sustaining the body temperature during 
anesthesia. The rats were allowed to recover after the operation as previously 
described. Saline injected rats were used as controls.  
4.1.2 Focal myelin oligodendrocyte glycoprotein EAE (fMOG-
EAE) 
Likewise with fDTH-EAE, fMOG-EAE model was also set up in two phases. 
However, the fMOG-EAE rats were first MOG-immunized under anesthesia by 
injecting s.c. 150 μL of rat MOG (35–55) peptide (Sigma Aldrich, St. Louis, MO, 
USA) emulsified in IFA (Sigma-Aldrich, St. Louis, MO, USA) to the base of the 
tail. Then 21 days post MOG-immunization, the rats were placed into the stereotactic 
frame and drilled as described earlier and operated by a stereotactic injection of 2-
μL cytokine mixture including 1 μg recombinant rat interferon-γ (IFN-γ, Sigma-
Aldrich, St. Louis, MO, USA) and 1.45 μg of recombinant rat tumor necrosis factor-
α (TNF-α, Sigma-Aldrich, St. Louis, MO, USA) into the corpus callosum at the 
depth of 2.5 mm from the surface of the cortex over a 10 min period to induce a 
targeted focal EAE lesion. The sham-operated rats were injected with 2 μL of saline. 
This sensitation procedure combined with injection of cytokine mixture will create 
more diffuse inflammatory lesions that exhibit transient cortical demyelination and 
have B cells involved in the pathogenesis, which is a common feature in patients 
with MS (Frohman et al., 2006, Lucchinetti et al., 2000, Serres et al., 2009, Racke et 
al., 2008). 
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4.2 Radiochemistry 
4.2.1 Radiosynthesis of 68Ga-DOTA-Siglec-9 
DOTA-Siglec-9 is a cyclic peptide consisting of residues 283−297 from the Siglec-
9 and it has a polyethylene glycol derivative linker (8-amino-3,6-dioxaoctanoyl) in 
between the peptide (Peptide Specialty Laboratories, Heidelberg, Germany) and 
DOTA chelate. The cyclic rings in DOTA-Siglec-9 are covalently bound with 
disulfide-bridged cysteines. For labeling purposes, 68Ga was acquired from a 
68Ge/68Ga generator (Eckert & Ziegler, Valencia, CA, USA) by elution with 0.1 M 
hydrochloric acid. 68Ga eluate (0.5 mL, 320 ± 30 MBq) was mixed with 2-[4-(2-
hydroxyethyl)piperazin-1-yl] ethanesulfonic acid (HEPES) to adjust the pH to 
approximately 4.1. 3 nmol of DOTA-Siglec-9 dissolved in deionized water was 
added and the then heated at 100°C for 15 min. Overall radiochemical purity for 
68Ga-DOTA-Siglec-9 was > 95% throughout the Study I and the specific 
radioactivity at the end of synthesis was 180 ± 140 MBq/nmol. The radiochemical 
purity of 68Ga-DOTA-Siglec-9 was evaluated by radiodetector-coupled high-
performance liquid chromatography (HPLC) (Jupiter C18 column, 4.6 × 150 mm, 
300 Å, 5 μm; Phenomenex, Torrance, CA, USA). For the HPLC-analysis, solvent A 
was water including 0.1% trifluoroacetic acid (TFA) and B solvent consisted of 0.1% 
TFA and acetonitrile. A to B gradient was set from 82/18 percent during first 2 min 
to transition from 82/18 to 40/60 during time period from 2 to 11 min and remained 
at 40/60 from 11 to 14min. At 14 min, the gradient was returned back to 82/18 over 
1 min time frame. Finally, the gradient was set to 82/18 at 15 min to 20 min. The 
flow rate was adjusted to 1 mL/min and ultra violet (UV) detection to 215 nm.68Ga-
DOTA-Siglec-9 is presented in Figure 3. 
 
Figure 3.  The chemical formula of [68Ga]-DOTA-Siglec-9 (Modified from Virtanen et al., 2015). 
4.2.2 Radiosynthesis of Al18F-NOTA-Folate (18F-FOL) 
Synthesis of 1,4,7-triazacyclononane-1,4,7-triacetic acid (NOTA)-folate conjugate 
was prepared according to a previously published method (Chen et al., 2016). The 
radiolabeling was initiated by eluation of 18F-fluoride (3.2–3.4 GBq) in saline 
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(50 µL) and then transformed to a reaction vessel containing sodium acetate buffer 
(pH 4.0, 1 M, 25 µL) and aluminium chloride (AlCl3) (2 mM). The reaction mixture 
was kept at room temperature for 3 min and the NOTA-folate (250 µg) in water 
(50 µL) and acetonitrile (125 µL) was added. The reaction vessel was heated at 
100 oC for 15 min. The reaction mixture was diluted with water containing 0.1% 
formic acid (1 mL) and subjected to HPLC purification with a semi-preparative C18 
column (Jupiter 250 × 10 mm, Phenomenex Inc., Torrance, CA, USA) with both UV 
(254 nm) and radioactivity detection. Water containing 0.1% formic acid was used 
as a solvent A and solvent B contained acetonitrile and mixture of 0.1% formic acid. 
The elution was programmed as A/B gradient from 92/8 to 79/21 over 20 min with 
a flow rate of 4 mL/min. A solution of potassium bicarbonate (KHCO3) in water (1 
M) was added to adjust the collected HPLC fraction to pH 5.5 and the solvents were 
evaporated. The residue was formulated in phosphate-buffered saline (PBS) 
containing 8% ethanol and 7% polypropylene glycol. The total synthesis time was 
77–88 min starting from end of bombardment. Another HPLC analysis was 
performed at the end product on an analytical C18 column (Jupiter 250 × 4.6 mm, 
Phenomenex Inc., Torrance, CA, USA) using both UV (254 nm) and radioactivity 
detection as previously. This time, solvent I was water containing 0.1% TFA and 
solvent II was acetonitrile containing 0.1% TFA. The I/II elution gradient was 
programmed from 90/10 to 75/25 over 15 min with a flow rate of 1 mL/min. The 
radiochemical purity was >95% and molar activity was 52 ± 22 GBq/µmol. The 
decay-corrected radiochemical yields were 28 ± 7%, respectively. The final 
compound is shown in Figure 4. 
 
Figure 4.  The chemical formula of Al[18F]-NOTA-Folate, 18F-FOL (Modified from Chen et al., 
2016). 
4.2.3 Radiosynthesis of 11C-PBR28 
The radiochemical synthesis of N-acetyl-N-(2-[11C]methoxybenzyl)-2-phenoxy-5-
pyridinamine (11C-PBR28) is adapted from the published method (Wang et al., 
2009). Cyclotron-produced [11C]methane was halogenated by gas phase reaction into 
[11C]methyl iodide, converted online into [11C]methyl triflate and introduced in a 
solution of desmethyl precursor (dm-PBR28, 0.30–0.40 mg, PharmaSynth AS, 
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Tartu, Estonia) in acetone (200 µl) and sodium hydroxide (0.5 M sodium hydroxide 
(NaOH), 2.5 µl) at 0 °C. 
After 3 minutes reaction at 80 °C, the reaction product was purified using a semi-
preparative HPLC column (ACE C18-HL, 5 µm, 10 × 250 mm, Advanced 
Chromatography Technologies Ltd, Aberdeen, Scotland) and acetonitrile (CH3CN) 
in 0.02 M potassium dihydrogenphosphate (KH2PO4) (43:57) mobile phase at 
7 ml/min flow rate. The eluent was monitored for 254 nm UV absorbance and 
radioactivity. Collected product fraction was diluted and loaded into a solid phase 
extraction C18 cartridge (Sep-Pak Light, Waters Corp., Milford, MA) and the 
cartridge was washed. Dilution and washing were done using five percent ethanol in 
water solution. 
The product was extracted with ethanol from the SPE cartridge, diluted with 
0.1 M phosphate buffer solution into < 10% ethanol level and finally sterile filtered 
(Millex GV, 0.22 µm polyvinylidene fluoride membrane, 33 mm, Merck Millipore). 
Determination of identity, radiochemical purity, and mass concentration was 
performed using analytical HPLC column (Kinetex XB-C18, 2.6 µm, 3.00 × 50 mm, 
Phenomenex Inc., USA ), CH3CN in 0.02 M KH2PO4 (35:65) mobile phase, 
1 mL/min flow rate, 5 min run time and detectors in series for UV absorption (210 
nm) and radioactivity. [11C]PBR28 was produced with >99.9% radiochemical purity 
and averaged molar activity of 680 ± 270 MBq/nmol at the end of synthesis. 
[11C]PBR28 is displayed in Figure 5. 
 
Figure 5.  The chemical structure of [11C]-PBR28 (Modified from Imaizumi et al., 2007). 
4.2.4 Radiosynthesis of 68Ga-NOTA-Folate (68Ga-FOL) 
The precursor compound of NOTA-folate was synthesized as earlier described and 
radiolabeled with gallium-68. 68Ga was obtained from a 68Ge/68Ga generator (Eckert 
& Ziegler, California, USA) by elution with 0.1 mol/L aqueous hydrochloric acid. 
68Ga eluate (1.0 mL) was added to a mixture of 2-[4-(2-hydroxyethyl)piperazin-1-
yl]ethanesulfonic acid (120 mg), gentisic acid (0.3 mg) and NOTA-Folate (17 µg) in 
120 µL TraceSELECT grade water. The reaction mixture was heated at 80°C for 
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10 min. After cooling down with an ice bath to approximately r.t, aqueous NaOH 
solution (1 M) was used to adjust the pH to neutral. Radiochemical purity of 68Ga-
FOL was determined with HPLC on a reversed phase column (Jupiter C18 column, 
4.6 × 150 mm, 300 Å, 5 μm; Phenomenex, Torrance, CA, USA). The HPLC 
conditions were as follow: flow rate was 1 mL/min; solvent A was 0.1% TFA/water 
and solvent B was 0.1% TFA/acetonitrile. A/B gradient: 0–0.5 min, 95/5; 0.5–15 
min, from 95/5 to 75/25. The HPLC system consisted of LaChrom Instruments 
(Hitachi; Merck, Darmstadt, Germany) and of a Radiomatic 150TR radioisotope 
detector (Packard, Meriden, CT, USA). 68Ga-FOL was prepared in high 
radiochemical purity (>95%). Duration of radiosynthesis was approximately 17 min. 
68Ga-FOL is displayed in Figure 6.  
 
Figure 6.  Chemical structure of [68Ga]-NOTA-Folate (68Ga-FOL). 
4.3 PET studies 
4.3.1 In vivo multimodal PET/CT imaging 
In all of the studies, in vivo PET/computed tomography (CT) images were acquired 
with Inveon multimodality small animal PET/CT scanner (Siemens Medical 
Solutions, Knoxville, TN, USA). The detector of the Inveon small animal PET/CT 
scanner consist of 80 crystal rings, which include 25600 crystals in total. Its spatial 
resolution ranges between 1.2 mm3 and 1.6 mm3 depending on the radioisotope used 
(Goertzen et al., 2012). This PET/CT generates an axial field of view (FOV) of 12.7 
cm and transaxial field of 10 cm. To start the in vivo PET/CT data acquisition, the 
animals were anesthetized on a heating pad using a mixture of isoflurane and air as 
previously described and a cannula was placed into the tail vein prior to radiotracer 
injection. A 10-min CT scan was performed prior to PET imaging for anatomical 
references and attenuation correction. Depending on the study, either 60-min, 45-
min or 30min-dynamic PET acquisition was started after an intravenous (i.v.) tail 
vein injection. (Study I, 68Ga-DOTA-Siglec-9, 45 min-dynamic, 34 ± 5.1 MBq, 
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n = 32; Study II, 18F-FOL, 60-min dynamic, 38.9 ± 2.7 MBq, n = 21 and 11C-PBR28, 
30 min-dynamic, 34.1 ± 3.5 MBq, n = 12; Study III, 68Ga-FOL, 30 min-dynamic, 
45 ± 1 MBq, n = 40). The PET data was reconstructed using an ordered subsets 
expectation-maximization 2-dimensional maximum a posteriori algorithm to yield 
6 × 10, 9 × 20, 4 × 60, 4 × 180, and 2 × 300 s time frames. For the in vivo PET data 
analysis, the PET images were aligned to the corresponding CT and MRI data sets 
and analyzed with Carimas v2.9 (Carimas, Turku PET Centre, Turku, Finland) with 
the exception of the study III where MRI data was absent. Representative PET/CT 
and MRI images were captured using Inveon Research Workplace v4.1 (Siemens 
Medical Solutions). The quantitative PET data was analyzed by defining a ROI in 
the injected lesioned hemisphere and this ROI was then mirrored onto the 
contralateral non-injected hemisphere to function as an internal reference region. 
These results were expressed as standardized uptake value (SUV) ratios according 
to the following equation:  
SUV ratio = SUVmax,Lesion/SUVmean, Contralateral 
In this equation, SUV values are defined as radioactivity concentration in a ROI 
(MBq/mL), which is normalized for injected radioactivity dose (MBq/mL) and 
animal body weight (kg). 
4.3.2 Ex vivo autoradiography & gamma counting 
After the in vivo PET/CT imaging, the anesthetic was increased to a terminal level 
(4–5% isoflurane; and oxygen, 500–700 mL/min) and blood was extracted from the 
left ventricle of the heart via cardiac puncture. Cervical dislocation was performed 
to confirm the euthanasia. Then, the rats brains were carefully dissected, frozen in a 
cold isopentane at a temperature of −70°C, and sectioned (20 μm for ex vivo 
autoradiography and 10 μm for histology) in a microtome (Leica CM 3050S cryostat, 
Leica Biosystems, Nussloch, Germany). Coronal brain sections were cut from 
striatum (at lesion site) and cerebellum and placed on to positively charged glass 
slides (Superfrost Ultra Plus, Thermo Fisher, Pittsburgh, PA, USA). The sections cut 
for autoradiography (20μm sections) were then exposed to a phosphor imaging plate 
(BAS-TR2025, Fuji Photo Film Co, Ltd., Tokyo, Japan) for periods of 220 min (i.e., 
two physical half-lives of 18F), 40 min (i.e., two physical half-lives of 11C) or 140 min 
(i.e., two physical half-lives of 68Ga) depending on the isotope and scanned with a 
phosphor imaging plate reader (BAS-5000, Fuji; 25 μm internal resolution) to 
acquire the data. Finally, both the 10 µm and 20 µm sections were frozen at −20°C 
for histological, immunohistochemical and immunofluorescence evaluation. The 
acquired ex vivo autoradiography data were analyzed with AIDA Image analyzer 
v4.55 software (Raytest Isotopenmessgeräte GmbH, Straubenhardt, Germany) by 
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drawing the ROIs in the lesions hemisphere and mirroring the corresponding ROI to 
contralateral hemisphere for obtaining the count densities as photostimulated 
luminescence per square millimeter (PSL/mm2) of 18F-FOL, 11C-PBR28 or 68Ga-
FOL binding within ROIs. Cortical ROI’s were also determined to cover the extent 
of radiotracer binding surrounding the lesion. The following equation was used for 
data quantitation and formation of the bound-to-free ratio of the radioligand: 
[(PSL/mm2 Lesion - PSL=mm2 Contralateral) = PSL/mm2 Contralateral] 
For the ex vivo gamma counting, the excised tissues including the brain were 
weighted and measured with a gamma counter (Triathler 3′′, Hidex, Turku, Finland) 
to obtain the biodistribution of the radioactivity. 
4.3.3 In vitro studies 
In vitro binding of 18F-FOL and 68Ga-FOL in fDTH-EAE lesions were determined 
to evaluate the specificity of radiotracers to FR. Firstly, the 20 μm brain tissue 
cryosections were pre-incubated in sterile PBS at room temperature for 15 min, and 
thereafter with 0.2 nM 18F-FOL or 68Ga-FOL in sterile PBS. One group of slides was 
incubated with 18F-FOL or 68Ga-FOL and other groups received a 100-fold molar 
excess of folate glucosamine (C25H30N8O10; molecular weight, 602.56) prior to 
applying the radiotracer for 30 min. After the incubation period, the slides were 
washed with ice-cold PBS, placed in ice-cold distilled water, briefly dried, and 
predisposed to a phosphor imaging plate (BAS-TR2025, Fuji Photo Film Co, Ltd., 
Tokyo, Japan) for 220 min (18F-FOL) or 140 min (68Ga-FOL). Finally, the imaging 
plates were scanned with the imaging plate reader (BAS-5000, Fuji; 25μm internal 
resolution). The in vitro autoradiography data was analyzed as described above 
regarding ex vivo autoradiography experiments. 
4.3.4 In vivo stability of 18F-FOL and 68Ga-FOL 
For measuring the stability of 18F-FOL and 68Ga-FOL, blood samples from healthy 
Lewis rats (Study II, n = 12, Study III, n = 16) were collected at 2–60 min after 18F-
FOL injection and at 5-30 min after 68Ga-FOL injection into heparinized tubes. A 
gamma counter (1480 Wizard 3″; Perkin Elmer/ Wallac, Turku, Finland) was used 
to measure the radioactivity concentration of whole blood and plasma samples. To 
separate plasma proteins from plasma, equal volume of acetonitrile was added to 
each sample followed by centrifugation 2100×g at room temperature for 4 min. Post 
centrifugation, the plasma supernatant was filtered through a 0.45 μm Minispike 
filter (Waters Corporation, Milford, MA, USA) for HPLC analysis. This HPLC 
analysis was conducted using a semipreparative C18 column (Jupiter Proteo 90Å, 
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4 μm, 250 × 10mm, Phenomenex Inc., Torrance, CA, USA) for both the ultraviolet 
(254 nm) and radioactivity detection of the plasma samples. Solvents A and B were 
of same content as with HPLC analysis of radiotracer synthesis. However, the elution 
was programmed with modifications as follows: flow rate was 5 mL/min, 8% B 
during 0–1 min, from 8 to 23% B during 1–14 min, and from 23 to 8% B during 14–
15 min. The fraction of intact tracer remaining in the plasma was determined by 
comparing this fraction with 18F-FOL or 68Ga-FOL standard depending on the study. 
By utilizing the population-based information of plasma radioactivity, the dynamic 
PET images of fDTH-EAE rats were analyzed by the Logan method of reversible 
modelling. The data was corrected for metabolites using an image-derived input 
function from the ROI defined on the left ventricle of the heart.  
4.4 MRI studies 
In the Study I and II, MRI data was acquired using clinical Philips Achieva 3T device 
(Philips Medical Systems, Koninklijke, The Netherlands) combined with rat-
dedicated brain coil (Rat Brain Array 4, RAPID Biomedical GmbH, Rimpar, 
Germany). Anesthesia was initiated as described for in vivo PET imaging. Then, a 
cannula was inserted  into the tail vein for the administration of 100 μL of the Gd-
contrast agent (DOTAREM 279.3 mg/mL, Guerbet, Roissy, France) 10 min prior to 
the post T1-weighted imaging for ascertainment of BBB status. First, scout images 
were acquired to determine the area to be scanned from the brain. Pre and post T1-
weighted spin-echo sequences were obtained by using the time of repetition (TR) of 
600 ms and echo time (TE) of 14 ms. The T2-weighted images were obtained using 
the turbo spin-echo (TSE) sequence, which included parametric values as TR 4000 
ms, TE 75 ms and TSE factor 10. The FOV was 45 mm × 45 mm × 21.6 mm for the 
T2-weighted images and 50 mm × 50 mm × 17.6 mm for the T1-weighted images. 
MRI data were analyzed in the study I using Inveon Research Workplace v4.1 
software (Siemens Medical Solutions, Malvern, PA, USA) and used only as an 
anatomical reference for drawing ROI’s in PET images in the study II. In the study 
I, post T1-weighted and T2-weighted images were first thresholded according to the 
signal intensity in non-injected brain hemispheres. Post T1-weighted and T2-
weighted hyper-intnsity MR images were assessed by defining ROIs on the area of 
Gd-enhancement and the ROI’s were mirrored on the contralateral intact brain 
hemisphere. The results were expressed as lesion to contralateral intact brain 
hemisphere ratios. 
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4.5 Experimental designs 
In the Study I, both fDTH-EAE and fMOG-EAE rats were divided into two groups 
and PET/CT imaged on day 3 (n = 8) and on day 14 (n = 8). A subset of fMOG-EAE 
rats were intraperitoneally administered daily with a selective semicarbazide-
sensitive amine oxidase (SSAO) inhibitor Z-3-fluoro-2-(4-methoxybenzyl) 
allylamine hydrochloride, (LJP1586, SYNthesis med chem, Monash Institute of 
Pharmaceutical Sciences, Melbourne, Australia), 5 mg/kg (n = 8) and imaged as 
mentioned for other groups. Sham-operated rats (n = 8) were used as controls. For 
the Study II, fDTH-EAE rats were imaged with 18F-FOL (n = 15) or 11C-PBR28 (n 
= 8) at day 14 and re-evaluated with 18F-FOL (n = 6) or 11C-PBR28 (n = 4) at day 90 
before the sacrifice. In the study III, fDTH-EAE rats (n = 60) were divided into six 
groups according to the intervention, disease duration and health status. The first two 
groups of fDTH-EAE rats imaged at day 14 (n = 20) were administered s.c. with 
folate aminopterin drug of Endocyte (EC2319) (500 nmol/kg/day) or saline on days 
0, 3, 7, 10 after the disease induction. The rats studied for the chronic phase were 
first imaged at day 60 (n = 20) and the second time at day 90. Between the baseline 
and follow-up PET/CT imaging, the fDTH-EAE rats were biweekly administered 
with EC2319 (750 nmol/kg/day) for four weeks. Additional (n = 20) healthy rats 
were also treated with EC2319 (500 nmol/kg/day) or saline as for rats during acute 
phase group (day 14). 
4.6 Immunohistochemistry & Immunofluorescence 
for pre-clinical experiments 
The histological stainings were performed by first fixing the 10µm sections with 
either acetone or formalin, which was determined based on the optimization data and 
then stained with hematoxylin-eosin (H&E) or Luxol Fast Blue (LFB) with cresyl 
violet counterstain using standard procedures. For immunohistochemistry, the 
sections were post-fixed with periodate-lysine-paraformaldehyde for 20 min and 
washed three times with PBS. Antigen retrieval was performed after the fixation in 
a hot citrate buffer (pH 6.0) in order to improve antibody binding. Then the sections 
were processed with a quenching step in which the 1% hydrogen peroxide (H2O2) in 
methanol is blocking the endogenous peroxidase and washed with PBS. Then the 
desired primary antibody: anti-cluster of differentiation 11b/c (OX-42), (OX-42, 
1:100 dilution, Abcam, Cambridge, UK), anti-inducible nitric oxide synthase (iNOS, 
1:500 dilution, Abcam, Cambridge, UK), anti-mannose receptor C-type 1 (MRC-1, 
1:2000 dilution, Abcam, Cambridge, UK), anti-cluster of differentiation 68 (CD68) 
(1:1000 dilution, AbD Serotec, Hercules, CA, USA) and anti-FR-β (1:50 dilution, 
m909, a kind gift from Professor Philip S. Low, Purdue University, West Lafayette, 
IN, USA) to study FR-β expression (Feng et al., 2011), was added for a 1h 
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incubation. The primary antibody incubation was followed by the addition of a 
secondary antibody: for OX-42, Dako EnVision anti-mouse Ig (Code K4001), for 
anti-iNOS, Dako EnVision anti-rabbit (Code K4003), for anti-MRC-1, Dako 
EnVision anti-rabbit (Code K4003), for anti-CD68, Dako EnVision anti-mouse 
(Code K4001), (4) for anti-FR-β, Dako (Code P0397) Streptavidin, for 30 min. 3,3-
diaminobenzidine (DAB, Dako; Code K3468) was used as a chromogen for the 
detection of antibodies. Counterstaining was conducted with hematoxylin and then 
sections were mounted with ProLong Gold antifade reagent (Life Technologies 
P36930). 
For neurofilament protein (NFP) and IgG immunohistochemical staining, the 
cryosections were processed as described above except washes in between the 
procedures was performed with PBS supplemented with 0.05% Tween-20. Then, the 
sections were incubated with anti-NFP antibody (M0762, clone 2F11, Dako, Santa 
Clara, CA, USA) for 1h and followed by the addition of a secondary anti-rat Ig 
antibody (Dako, K4001). IgG leakage was assessed with incubating the sections with 
only anti-rat Ig (Dako, K4003). After DAB reaction, sections were further processed 
as described above. 
H&E stained sections were used for evaluating lesion size and quantifying 
lymphocyte infiltration as lymphocyte count densities per mm2. For lymphocyte 
quantification, four non-overlapping areas within the lesion area were chosen 
according to the highest density of recruited lymphocytes. The amount of activated 
microglia in the injected hemisphere was determined by drawing ROIs on the 
subjectively estimated area of increased microglial activation. The degree of 
demyelination was scored from 0 to 3 or determined by using the automatic color 
deconvolution method of ImageJ v.1.48 software (National Institutes of Health, 
Bethesda, MD, USA) based on LFB staining intensity. The percent area of altered 
NFP expression or IgG leakage were determined by defining ROIs on positive 
immunostained areas. These areas were defined on four brain sections and averaged 
for each rat. Finally, the average areas were divided by the total averaged brain area 
for each rat. 
For double immunofluorescence of FRβ and MRC-1 or FRβ and iNOS, the 
sections were fixed with ice-cold formalin for 3min and washed with PBS. Then, the 
slides were incubated with primary anti-FRβ (1:50 dilution, m909) and anti-MRC-1 
antibodies (1: 2000 dilution, Abcam) or with anti-FR-β and anti-iNOS antibodies 
(1:500 dilution, Abcam) for 30min at room temperature. Thereafter, the sections 
were incubated with fluorophore-labeled secondary antibodies (1:100 dilution, 
Alexa Fluor 488 or Alexa Fluor 594, Invitrogen, Waltham, MA, USA). 
For P-selectin and intercellular adhesion molecule-1 (ICAM-1) 
immunofluorescence, the samples were incubated either with primary anti-P-selectin 
antibody (Santa Cruz sc-6943; 1:100 dilution) or with anti-ICAM-1 antibody (Santa 
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Cruz sc-7891; 1:20 dilution) for 30 min in room temperature followed by incubation 
with fluorescein isothiocyanate (FITC)-conjugated goat anti-rabbit secondary 
antibody (Sigma F1262-2ML; 1:100 dilution) and the amplification of the signal 
with anti-Fluorescein-488 (Invitrogen A11096, 5 μg/mL). For VAP-1 
immunofluorescence, the sections were incubated only with FITC-conjugated 
(Sigma F1262; 1:40 +5% normal rat serum) goat anti-rabbit IgG secondary antibody 
(Life Technologies A11034) for the detection of luminal VAP-1 on the surface on 
the endothelial cells. For a subgroup of slides, polyclonal anti-VAP-1 antibody 
(rabbit anti-human VAP-1 that also recognizes rat VAP-1) was applied for 30 min 
to visualize both intracellular and surface-bound VAP-1 (Kivi et al., 2009). The 
sections were mounted as described with immunohistochemical stainings. 
All immunohistochemical and immunofluorescence stainings were scanned 
using Pannoramic 250 F scanner or Pannoramic Midi fluorescence scanner (3D 
Histech, Budapest, Hungary) and analyzed with Case viewer (3D Histech, Budapest, 
Hungary). The percentages of positive staining area for iNOS, MRC-1, CD68, and 
FR-β were determined as with immunohistochemical stainings. 
4.6.1 Human tissue samples 
Human brain tissue samples were obtained to investigate the FR-β, iNOS, MRC-1 
and CD68 positivity in healthy human brain and in brains affected with SPMS. For 
the stainings, human formalin-fixed paraffin embedded samples were acquired from 
Auria Biobank (Turku University Hospital, Turku, Finland) with the criteria of active 
or inactive chronic MS plaques located in the brain or spinal cord. On the other hand, 
normal brain tissue samples were collected from corresponding anatomical areas of 
the brain compared to samples from patients with MS. The approval for the archival 
human tissues study was granted by the Auria Biobank scientific steering committee 
(decision AB19-2623). A separate patient informed consent was not needed 
according to the Finnish Biobank Law (688/2012). All samples had been attained for 
histopathologic examination during autopsy between years 2001 and 2013. For the 
immunofluorescence and for the immunohistochemistry, the samples were stained 
as described previously for pre-clinical experiments. Positivity for FR-β 
immunohistochemistry was graded as either negative, weak, moderate, or strong 
based on the intensity of the staining. 
4.7 Statistical analyses 
All statistical analyses related to this thesis work were conducted with GraphPad 
Prism v5.01 or 8.04 software (Graph Pad Software Inc., La Jolla, CA, USA). Non-
parametric Kruskal-Wallis tests with Mann-Whitney post hoc tests were used to 
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evaluate the significance of differences in lesion tracer uptake between the studied 
groups. Intragroup comparison for histological, immunohistochemistry and 
immunofluorescence data was also conducted by using non-parametric Kruskal-
Wallis tests with Mann-Whitney post hoc tests. To analyze longitudinal PET 
imaging studies regarding 11C-PBR28, 18F-FOL and 68Ga-FOL, Wilcoxon matched-
pairs test was performed. Spearman’s correlation was used to analyze relationships 
between PET data, immunohistochemistry and histology. Results are presented as 
mean ± standard deviation with two significant numbers. The results that indicate P 
values under 0.05 were regarded statistically significant in the studies. 
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5 Results 
5.1 MRI analysis of fMOG-EAE and fDTH-EAE 
lesions 
Lewis rats induced with fDTH and fMOG lesions were imaged with 3-T MRI 
combined with rat dedicated brain coil to showcase the availability of clinical MRI 
for pre-clinical research without the use of high-resolution MRI. Our MRI analysis 
in the study I revealed that this method could visualize the characteristics of a typical 
active Type 1 MS-like lesion with significantly increased Gd-enhancement in T1-
weighted images indicating BBB disruption and areas of hyperintensity in T2-
weighted MRI images (P < 0.05). Pre-active lesions that only show small scale 
damage were not observed T1-weighted Gd-enhanced or T2-weighted images 
(Figure 7). On the other hand, Type 2 lesions were clearly visible in T1-post Gd-
enhanced and T2-weighted MRI showing an acute, widespread and diffuse 
inflammation already two days after disease induction accompanied by BBB 
breakdown. After the partial resolvement of fMOG-EAE lesions at day 13, the T2-
hyperintense area (P < 0.05) and Gd-enhanced areas in T1-weighted images 
(P < 0.001) were significantly reduced indicating improved BBB status during 
remission (Figure 7). 
These MRI findings were supported by OX-42 and IgG immunohistochemistry 
showing low amounts of OX-42 positive microglia for pre-active lesions and 
significantly higher levels of OX-42 positivity in acute phase of fDTH lesions 
compared to pre-active lesions (P = 0.039). IgG staining was minimal during the pre-
active phase and was detected in significantly higher levels at acute phase (P < 0.05). 
For the fMOG-EAE, the OX-42 immunohistochemistry showed significantly larger 
areas of OX-42 positive cells compared to remission at day 13 (P = 0.0024) and IgG 
leakage indicated marked improvements at remission when compared to IgG 
positivity at acute phase (P < 0.05). 
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Figure 7.  MRI images acquired on days 2 and 13 from fDTH-EAE, fMOG-EAE and fMOG-EAE 
rats treated with LJP 1586. Red arrows indicate lesion site. Post-contrast T1-weighted 
images illustrate the BBB status at various stages of disease and demonstrate Gd-
enhancement in the lesion during BBB damage. T2-weighted images show the 
formation and partial resolvement of a hyperintense region. LJP 1586 administration 
prevents recovery of the hyperintense and Gd-enhanced areas (Modified from Study I). 
5.2 Evaluation of VAP-1 expression and 68Ga-
Siglec-9 binding in inflammatory EAE lesions 
We observed in the study I that luminal VAP-1 expression in fDTH-EAE appeared 
in the lesion vasculature post pre-active lesion development only during active 
inflammatory phase. Immunofluorescence data only showed occasional VAP-1 
positivity in brain tissue and total lack of VAP-1 translocation in the lesion area. This 
was supported by a weak 68Ga-DOTA-Siglec-9 ex vivo autoradiography signal 
(Figure 8). There was no evidence of demyelination during VAP-1 absence. During 
the acute inflammatory phase, the immunofluorescence stainings indicated higher 
signal for luminal VAP-1 compared to the pre-active phase. 68Ga-DOTA-Siglec-9 
binding was significantly elevated at the site of fDTH-EAE lesion during the acute 
phase. (3.2 ± 0.59 vs. 0.16 ± 0.22 PSL/mm2, P = 0.0031) (Figure 8). The VAP-1 
immunofluorescence signal of endothelial cells in fDTH-EAE reminded the structure 
of regular flat-walled endothelial cell morphology, which is typically found in 
smaller and thinner venules. The LFB staining now revealed demyelinated areas 
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present around the lesions although the difference was not statistically significant 
when compared to pre-active lesions (P = 0.13). 
When fMOG-EAE rats representative of Type 2 immunopathology were 
examined, the expression patterns of VAP-1 were substantially altered from rats with 
fDTH-lesions (Figure 8). Immunofluorescence stainings exhibited high amounts of 
positivity for luminal VAP-1 both during acute widespread inflammation and the 
remission phase. In lines with VAP-1 positivity, 68Ga-DOTA-Siglec-9 binding was 
significantly elevated in the injected lesion hemisphere at acute phase (P = 0.017) 
and a remission phase (P = 0.055) as compared to the sham-operated rats. However 
at day 14, the 68Ga-DOTA-Siglec-9 binding remained at the same level compared to 
day 3 (P = 0.17). As opposed to endothelial cells in fDTH-EAE, the endothelial cells 
in fMOG-EAE lesions displayed characteristics commonly observed in high 
endothelial venules (HEV)-like vessels (Girard et al., 1995) (Figure 8). There were 
moderate amount of demyelination at day 3 and no difference in demyelination score 
between the observed timepoints (P = 0.72). It could be stated that luminal VAP-1 
expression remained in the lesion vasculature once the fMOG-EAE rats had first 
experienced the acute inflammatory phase with compromised BBB. This pattern was 
detected by VAP-1 targeted 68Ga-DOTA-Siglec-9 ex vivo autoradiography and 
immunofluorescence with i.v. injected anti-VAP-1 antibody. 
 
Figure 8.  68Ga-Siglec-9 binding and VAP-1 positivity in fDTH and fMOG-EAE rats during the 
timecourse of the disease. Red arrows indicate VAP-1 positivity (green) from the 
autofluorescence (red). Scale bar is 50 µm (Modified from Study I). 
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5.2.1 The effect of VAP-1 inhibitor therapy on fMOG-lesions 
VAP-1 inhibitor treatment with LJP1586 inhibited the recruitment of lymphocytes 
by 58% (P = 0.026) at day 3 in fMOG-EAE compared to the number of lymphocytes 
in untreated rats at day 3. However during the remission phase at day 14, the amount 
of lymphocytes was restored to the same levels as observed with the untreated 
fMOG-EAE rats (P = 0.70). In addition, the administration of LJP1586 lowered the 
expression of ICAM-1 in the lesion vasculature for fMOG-EAE at acute phase until 
the expression patterns of ICAM-1 appeared to be slightly increased for LJP1586-
treated rats compared to untreated fMOG-EAE rats. Most importantly, VAP-1 
expression tended to decrease in the vasculature of the inflammatory fMOG-brain 
lesions due to LJP1586 intervention both at acute and remission phases of lesion 
development. The i.v. injected anti-VAP-1 antibody detects the endothelial cell 
surface VAP-1 and the secondary antibody applied during the immunostaining then 
detects the primary anti-VAP-1 antibody bound to the luminal side of endothelium, 
respectively. It is noteworthy that, the lesion size in fMOG-EAE was markedly larger 
at remission phase in the LJP1586-treated rats compared to untreated (P = 0.039). P-
selectin staining was negative during the entire time course of LJP1586-treated 
fMOG-EAE rats and untreated fMOG-EAE rats. In contrast, the LJP1586 treatment 
had no effect on the amount of OX-42-positive cells, the intensity of LFB staining, 
IgG leakage revealed by immunohistochemistry or the area of altered NFP 
expression in fMOG-lesions. Despite no difference was observed in IgG stainings 
between LJP1586-treated fMOG-EAE rats in acute and remission phases, a 
significant reduction of Gd-enhancement in MRI was observed at acute phase of 
fMOG-EAE (P = 0.0041). 
5.3 FR-β and macrophage marker expression 
during acute and chronic inflammation in fDTH-
EAE lesions 
In the Study II, the formation of fDTH-EAE lesions showed increased positivity for 
FRβ, CD68, iNOS (marker for M1-like pro-inflammatory macrophages) and MRC-
1 (marker for M2-like anti-inflammatory macrophages) as observed from 
immunohistochemistry. The positivity for FRβ, CD68, iNOS and MRC-1 exsisted 
during acute phases of inflammation and persisted or significantly intensified once 
the disease had progressed into chronic phase (Figure 9 A & B, Table 5). In more 
detail, the staining areas of anti-FRβ (P = 0.11), anti-CD68 (P = 0.23) and anti-MRC-
1 (P = 0.14) showed no statistical difference when the inflammation in fDTH lesions 
transitioned from acute to chronic phase. The computational ratio between iNOS and 
MRC-1 (iNOS/MRC-1) lacked the difference when acute and chronic phases were 
compared (Figure 9 C, P = 0.21). In contrast, the anti-iNOS positivity was 
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significantly higher in the chronic phase than in the acute phase (P = 0.019). 
Importantly, a significant proportion of anti-FRβ positivity and 18F-FOL uptake was 
found to be located in the areas of active demyelination and remyelination in fDTH 
lesions. 
The acquired correlation data suggested that the positive area of FRβ had 
significant negative correlation with CD68 area and iNOS/MRC-1 ratio when data 
from both time points were included from immnohistochemical stainings. In 
contrast, the correlation between the positive area of FRβ and MRC-1 was positive. 
The iNOS positivity and FRβ positivity lacked correlation (Table 5). 
 
Figure 9.  Example image of CD68, iNOS, FRβ and MRC-1 immunostainings for acute (day 14) 
and chronic (day 90) fDTH-EAE and quantification of corresponding 
immunohistochemical data. (A)  FRβ, CD68, iNOS and MRC-1 stainings show antibody 
specific staining at both phases of the disease. (B) Histogram of CD68, iNOS, MRC-1, 
FRβ immunohistochemistry and (C) iNOS/MRC-1 – ratio indicate significantly increased 
expression of iNOS positivity at chronic phase compared to acute phase. Positive 
staining area is normalized to lesion hemisphere area (positive area %). Scale bar 50 
µm. Key:* = P ≤ 0.05, NS = P ≥ 0.05 (Modified from Study II). 
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Table 5.  Correlation of FR-β immunostaining to iNOS, MRC-1, CD68 and iNOS/MRC-1 
immunostainings and to 18F-FOL and 11C-PBR28 radiotracer uptake in fDTH-EAE rats. 
 INOS MRC-1 FR-Β CD68 INOS/MRC-1 
 R2 P R2 P R2 P R2 P R2 P 
18F-FOL 0.43 0.076 0.22 0.24 0.13 0.37 0.60 * 0.23 0.23 
FR-Β 0.017 0.38 0.53 *** —  0.45 ** 0.39 *** 
11C-PBR28 0.24 0.26 0.37 0.15 0.01 0.81 0.48 0.64 0.16 0.37 
Key: *= P < 0.05, **= P < 0.01, ***= P < 0.001 
5.3.1 Comparison of 18F-FOL and 11C-PBR28 radioligands 
In the Study II, both 18F-FOL and 11C-PBR28 radioligands showed favorable 
properties for imaging neuroinflammationin in the rat model of MS representative 
of type I immunopathology. First, in vitro autoradiography of 18F-FOL indicated that 
the binding was specific to FR as brain cryosections pre-treated with folate 
glucosamine blocking agent showed significantly lower binding compared to non-
blocked sections (blocked, 0.44 ± 0.17 vs. non-blocked, 22 ± 1.2, P < 0.0001). 18F-
FOL was able to visualize the inflammatory CNS lesions in acute and chronic phases 
of inflammation in vivo, ex vivo and in vitro. In addition, 18F-FOL enabled the 
separation of acute and chronic inflammatory lesions only with digital ex vivo 
autoradiography (Figure 10A). The in vivo uptake of 18F-FOL co-localized with 
corresponding lesions observed in MRI (Figure 11A & B). Although, 18F-FOL 
binding managed to show significant difference compared to 11C-PBR28 at the 
chronic phase (P = 0.016), the differentiation of disease stages with the 18F-FOL 
imaged fDTH-EAE rats was not possible in vivo (Figure 11C). 
11C-PBR28 was able to visualize acute and chronic phase lesions ex vivo and in 
vivo. The uptake was present in the areas of corresponding MRI lesions as with 18F-
FOL. However, 11C-PBR28 lacked the ability to detect any differences between 
acute and chronic lesions both ex vivo and in vivo (Figure 10B & 11). To support the 
in vivo findings, a significant relationship was observed between ex vivo and in vivo 
measurements of both 18F-FOL (P = 0.0004) and 11C-PBR28 (P = 0.037) tracers. 
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Figure 10.  Ex vivo autoradiography of 18F-FOL and 11C-PBR28 PET imaging agents. A) Ex vivo 
autoradiography indicates high binding of 18F-FOL in the lesion hemisphere compared 
to the contralateral hemisphere during acute inflammation (red arrow). 18F-FOL binding 
is significantly more extensive during chronic inflammation (black arrow). Ex vivo images 
are supported by 18F-FOL quantification data. B) Ex vivo autoradiography exhibits 
binding of 11C-PBR28 in lesion hemisphere compared to contralateral hemisphere 
during acute inflammation (red arrow). 11C-PBR28 binding shows no significant 
difference between acute inflammation and chronic inflammation (black arrows). Ex vivo 
images are supported by 11C-PBR28 quantification data. Scale bar=2 mm. Key:* = P ≤ 
0.05, NS = P ≥ 0.05 (Modified from Study II).  
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Figure 11.  In vivo PET images and MR images of fDTH-EAE rat brain on acute (day 14) and chronic 
(day 90) phases of CNS inflammation with quantitative data. A) Representative coronal 
18F-FOL, 11C-PBR28 PET and MRI images during the acute phase. B) Representative 
coronal 18F-FOL, 11C-PBR28 PET and MRI images during chronic phase. C) In vivo PET 
quantitative data are presented as SUV-ratios (SUVmax, lesion/SUVmean, contralateral). Black 
and white arrows display the lesion site. Error bars denote standard deviation. Key:* = 
P ≤ 0.05, NS = P ≥ 0.05 (Modified from Study II). 
5.4 Folate aminopterin intervention and evaluation 
of 68Ga-FOL in acute and chronic fDTH-EAE 
EC2319, folate aminopterin drug-conjugate, treatment showed efficacy in the 
chronic phase of inflammation in fDTH-EAE as observed from immunofluorescence 
and histology in the study III. The anti-FR-β positivity was significantly lowered in 
EC2319-treated rats compared to saline-treated (P < 0.05) and the lesion size was 
also significantly reduced in rats treated with EC2319 compared to saline treated rats 
(P < 0.01). However, the area of CD68-positive macrophages/microglia (P = 0.093) 
and lymphocyte count densities (P = 0.065) demonstrated reduction for rats in 
EC2319 treatment group to that of saline treated rats, but the reductions did not result 
in significant difference. The immunofluorescence indicated significantly lowered 
iNOS/MRC-1-ratio (P < 0.01). 
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In vitro assay of 68Ga-FOL revealed significantly lower binding for 68Ga-FOL 
when the brain samples from chronic phase were pre-incubated with the folate 
glucosamine compared to total binding in which the samples had no pre-incubation. 
In addition, 68Ga-FOL binding was significantly reduced in brain samples that were 
EC2319-treated compared to saline-treated (P < 0.01). Although in vivo PET/CT and 
ex vivo autoradiography of 68Ga-FOL enabled the visualization of inflammatory 
lesions, these methods were unable to monitor the EC2319 therapy efficacy 
otherwise observed by anti-FR-β immunofluorescence and histology. 
For the acute phase of inflammation in fDTH-EAE, the corresponding 
immunofluorescence data indicated no differences in FR-β, CD68, iNOS or MRC-1 
positivity between EC2319 and saline treated groups. There was also no difference 
in iNOS/MRC-1-ratio, amount of lymphocytes and lesion size between EC2319-
treated rats and saline-treated rats. In vitro 68Ga-FOL assay, in vivo PET/CT imaging 
and ex vivo autoradiography revealed no differences between treatment groups. The 
EC2319 intervention data of acute and chronic fDTH-EAE rats is presented in more 
detail in Table 6.  
5.4.1 Expression of FR-β in human post-mortem MS brain 
and normal brain samples 
Immunohistochemistry of FR-β in the study III confirmed the presence of FR-β cells 
in brain parenchyma of patients with MS. The paraffin-fixed post-mortem MS brain 
sections showed FR-β positivity in areas of NAWM and in the chronic active lesions, 
which typically include vast amounts of activated microglia and macrophages, 
compared to normal brain sections that lacked the expression of FR-β in 
corresponding anatomical locations of NAWM (Figure 12). The 
immunofluorescence data support this assumption as FR-β expression in the MS 
brain is largely co-localized with CD68, iNOS (marker for M1 proinflammatory 
microglia/macrophages) and MRC-1 (marker for M2 anti-inflammatory 
microglia/macrophages) positivity (data not shown). This indicates that the results 
obtained from the fDTH-EAE are translatable to human MS to some extent. On the 
other hand, FR-β expression was very weak or absent in normal appearing grey 
matter (NAGM) and in chronic inactive lesions both know to have insignificant 
amounts of activated microglia and macrophages. The expression of FR-β was also 
very weak or negative in NAGM in normal brain samples (Figure 12 A). 
5.4.2 Modelling of 18F-FOL and 68Ga-FOL PET data  
In the Study II and III, the radiotracers 18F-FOL and 68Ga-FOL remained relatively 
stable in rat blood circulation (18F-FOL; 88% ± 0.12% intact tracer vs. 68Ga-FOL; 
Petri Elo 
 62
89% ± 2.81% at 30min post-injection) and the tracer uptake kinetics in the brain 
were well described by the Logan model for reversible binding. 
However, distribution volume ratio (DVR) for Logan analysis showed no 
significant difference in between 18F-FOL and 68Ga-FOL imaged fDTH-EAE rats at 
day 14 (P = 0.50) and at day 90 (P = 0.66). Additionally, brain to blood-ratios 
indicated no significant difference between 18F-FOL and 68Ga-FOL imaged fDTH-
EAE rats at acute phase of inflammation (at day 14, P = 0.47) and at chronic phase 
of inflammation (at day 90, P = 0.95). 
Interesting though, the DVR acquired from reversible Logan model for kinetic 
analysis (DVRLogan) correlated well with SUV-ratio of 18F-FOL imaged rats at the 
acute phase (R2 = 0.73, P < 0.05) and of 68Ga-FOL imaged rats at the chronic phase 
(R2 = 0.74, P < 0.05). The data is presented in Table 7.  
 
Figure 12.  Anti- FR-β immunohistochemical staining of formalin-fixed paraffin embedded human 
brain sections from MS and normal brain. FR-β staining A) of NAGM from SPMS patient 
and normal brain, B) of NAWM from SPMS patient and normal brain, C) of chronic active 
lesion and, D) of chronic inactive plaque. Red arrows display FR-β positivity. Scale bar 
is 50 µm. 
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Table 6.  Results of immunofluorescence, histology and 68Ga-FOL analyses from acute phase or 
chronic phase of fDTH-EAE rats treated with EC2319 or saline. 
 fDTH-EAE Day 
14 (Saline) 
fDTH-EAE Day 
14 (EC2319) 
P 
value 
fDTH-EAE Day 
90 (Saline) 
fDTH-EAE Day 
90 (EC2319) 
P 
value 
FR-β (mm2) 0.0030 ± 0.00088 0.0024 ± 0.0013 0.24 0.0064 ± 0.0016 0.0019 ± 0.00067 * 
CD68 (mm2) 0.0098 ± 0.0039 0.015 ± 0.0042 0.28 0.010 ± 0.0021 0.0053 ± 0.0011 0.093 
iNOS (mm2) 0.015 ± 0.0069 0.027 ± 0.0093 0.34 0.025 ± 0.011 0.0016 ± 0.0012 0.10 
MRC-1 (mm2) 0.0044 ± 0.0012 0.0040 ± 0.0016 0.89 0.0015 ± 0.00051 0.0022 ± 0.00065 0.63 
iNOS/ MRC-1 7.96 ± 5.80 8.62 ± 4.54 0.69 15.59 ± 2.24 0.63 ± 0.29 ** 
Lesion (mm2) 0.16 ± 0.043 0.71 ± 0.42 0.66 0.26 ± 0.098 0.055 ± 0.018 ** 
Lymphocytes 
(cells/mm2) 
956.4 ± 120.5 986.5 ± 118.6 0.89 729.80 ± 146.00 393.30 ± 84.66 0.065 
In vitro  
(bound-to-free) 
12.19 ± 0.77 13.97 ± 0.83 0.11 4.93 ± 0.43 2.47 ± 0.45 ** 
Ex vivo  
(bound-to-free) 
3.95 ± 0.98 10.16 ± 5.25 0.96 3.76 ± 1.75 0.75 ± 0.19 0.11 
In vivo (SUV) 4.01 ± 0.30 4.77 ± 0.27 0.10 3.79 ± 0.28 4.04 ± 0.30 0.55 
*= P<0.05, **=P<0.01, ***=P<0.001.  
Table 7.  Logan plot analysis and associations between SUV-ratios and DVRLogan of 18F-FOL and 
68Ga-FOL uptake in fDTH-EAE rats. 
 18F-FOL 68Ga-FOL 18F-FOL 68Ga-FOL 18F-FOL 68Ga-FOL 
 
DVR 
Lesion/ 
Contralateral 
DVR 
Lesion/ 
Contralateral 
Brain-to-Blood 
ratio Lesion/ 
Contralateral 
Brain-to-
Blood ratio 
Lesion/ 
Contralateral 
Correlation 
(R2) of SUV-
ratio and 
(DVRLogan) 
Correlation 
(R2) of SUV-
ratio and 
(DVRLogan) 
Day 14 1.19 ± 0.26 1.18 ± 0.18 1.18 ± 0.28 1.11 ± 0.17 0.73 0.19 
P 0.50 0.47 < 0.05 0.66 
Day 90 1.28 ± 0.30 1.22 ± 0.13 1.33 ± 0.32 1.32 ± 0.18 0.70 0.74 
P 0.66 0.95 0.19 < 0.05 
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6 Discussion 
6.1 Main findings of the studies 
In the Study I, we showed for the first time that the membrane-bound form of VAP-
1 is actively associated with the development of inflammatory lesions representative 
of type I and antibody-mediated type II immunopathology. Inhibition of membrane-
bound VAP-1 activity with a small molecular inhibitor LJP1586 prohibited the 
lymphocyte recruitment into lesion in the brain parenchyma during the acute 
inflammation in type II rat model of MS, but restored to same levels as without the 
LJP1586 treatment after the acute inflammation subsided at the remission phase. Ex 
vivo autoradiography results display that 68Ga-DOTA-Siglec-9 enabled detection of 
lesions that have evolved to traditional inflammatory lesions with active 
demyelination, lymphocyte recruitment, presence of activated macrophages and 
compromising of intact BBB. Luminal VAP-1 was not present during “pre-active” 
lesion development, which suggested that 68Ga-DOTA-Siglec-9 might not be 
considered as a promising radiotracer in early evaluation of MS-like pathologies. 
Thus, luminal VAP-1 was most likely expressed in lesion vasculature only after 
developed inflammatory lesions required amplification of immune response at the 
site of inflammation and the expression of VAP-1 remained on the lesion vasculature 
after the first active relapse during BBB restoration. In fMOG-EAE lesions the 
endothelium appeared to undergo a structural transformation from regular flat-
walled endothelium to HEV-like endothelium as the endothelial cells in fDTH-EAE 
lesions mostly displayed flat-walled morphology. The role of the luminal VAP-1 in 
EAE and possibly in MS might be related to amplifying inflammation in active 
demyelinating lesions and the function of VAP-1 in driving new lesion formation 
showed to be less significant of importance. 
In the Study II, we discovered the presence of FR-β expression in activated 
macrophages and microglia during the development of acute and chronic type I CNS 
inflammatory lesions in EAE. The FR-β expression was mostly detected in 
borderline of these lesions, which are known to have activated macrophages, 
ongoing demyelination and remyelination. Both of the studied radiotracers, 18F-FOL 
and 11C-PBR28 were able to identify the CNS lesions in acute and chronic phase of 
fDTH-EAE, but only 18F-FOL was able to separate between acute phase and chronic 
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phase lesions compared to 11C-PBR28. 18F-FOL exhibited also a significantly lower 
background than 11C-PBR28 overcoming a major limitation that conventional 
TSPO-targeted imaging still possesses especially during studies regarding 
neuroinflammation. Immunofluorescence and correlation data supported the view 
that FR-β expression is more prominent in MRC-1 positive macrophages and 
microglia (anti-inflammatory) than in iNOS positive macrophages and microglia 
(proinflammatory) in EAE. FR-β expression is also suggestive of equilibrium in 
iNOS/MRC-1 ratio known to be associated with milder inflammation in EAE. The 
18F-FOL binding was shown to be at highest in areas of the densest anti-MRC-1 
positivity, which indicates that 18F-FOL uptake could be located in the areas related 
to tissue remodeling and remyelination in neuroinflammation. 
In the III study, we examined the treatment efficacy of novel folate conjugate 
EC2319 for acute and chronic DTH-type lesions in EAE and the ability of 68Ga-FOL 
to visualize inflammatory lesions in vitro, ex vivo and in vivo, and demonstrate 
therapy efficacy of EC2319. The EC2319 was effective when administered at 
chronic phase of inflammation by reducing FR-β expression, iNOS/MRC-1 –ratio, 
lesion size, and also 68Ga-FOL binding in in vitro assay of brain sections. However, 
68Ga-FOL showed no significant change in in vivo and ex vivo uptake at either the 
chronic phase or the acute phase. In addition, the therapy efficacy observed at 
chronic phase was absent during acute phase of EAE. With regards to iNOS/MRC-
1 equilibrium post EC2319 treatment at chronic inflammation, the EC2319 might 
aid in the regulation of CNS inflammatory processess and therefore could introduce 
new therapeutic indications for folate aminopterin therapies outside the traditional 
scope of peripheral inflammatory disorders. This concept was very tempting as there 
have been very few approved therapies for primary progressive MS. However, it was 
noteworthy that the long-term efficacy and safety remained to be determined as 
EC2319 therapy reduced the number of FR-β positive cells required to FR-mediated 
endocytosis of the drug molecule. 
6.2 Evaluation of VAP-1 targeted 68Ga-Siglec-9 for 
PET imaging of MS-like lesions 
Based on the Study I, we can determine that luminal translocation of VAP-1 occurs 
in the vasculature of developed inflammatory lesions in rat models of MS that depict 
type I and II immunopathology and luminal VAP-1 can be used as a molecular target 
for imaging neuroinflammation. The data obtained from the digital ex vivo 
autoradiography suggests that 68Ga-DOTA-Siglec-9 can bind and visualize the 
inflammatory brain lesions positive for VAP-1 although the molar mass of 68Ga-
DOTA-Siglec-9 (C104H174N30O32S2, molecular weight 2.4202 kDa) exceeds 500 Da 
described in Lipinski’s rule (Virtanen et al., 2015, Oprea et al., 2001). This could be 
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explained by location of the molecular target, VAP-1, which is on the surface of the 
endothelium in blood vessels at the site of inflammation in the brain in fDTH-EAE 
and fMOG-EAE rats. The utility of 68Ga-DOTA-Siglec-9 has also been proven in 
previous preclinical studies in in vivo imaging of animal models of peri-implant 
infections, synovitis, atherosclerosis and tumor xenografts (Ahtinen et al., 2014, 
Virtanen et al., 2015, Silvola et al., 2016, Siitonen et al., 2019). The relatively 
abundant expression of membrane-bound VAP-1 during inflammatory processes in 
peripheral tissues is most certainly beneficial for the use of VAP-1 targeting 
radiotracers like 68Ga-DOTA-Siglec-9 in PET imaging of peripheral conditions 
compared to PET imaging of CNS inflammatory disorders. 
Our data in the study I suggested that VAP-1 expression is not found in the pre-
active lesions in fDTH-type lesions that typically lack the features of traditional CNS 
inflammatory lesions visible in MRI, such as ongoing demyelination, BBB 
disruption, macrophage and lymphocyte recruitment (Serres et al., 2009). Due to this 
68Ga-DOTA-Siglec-9 has very limited capacity for PET imaging of newly forming 
inflammatory MS-like lesions. This finding is unfortunate as tissue samples from 
early lesions in MS are challenging to obtain from living MS patients and discovery 
of molecular imaging marker for early stage lesions would be an important finding 
in the diagnostic field of MS (Pirko & Johnson, 2008). In contrast to early stage MS-
like lesions, 68Ga-DOTA-Siglec-9 was found to be successful in detecting lesions at 
the acute phase with widespread inflammation accompanied with BBB disruption in 
both type I and type II rat models of MS and lesions that show evidence of BBB 
restoration after the first acute relapse. Because perivascular lymphocyte and 
macrophage recruitment and BBB disruption occur during the relapse in MS 
(Alvarez et al., 2011, Minagar & Alexander, 2003), this discovery may be 
translatable to MS during relapses. Therefore, 68Ga-DOTA-Siglec-9 might have the 
ability to detect the inflammation-related alterations in the lesion after relapses and 
identify lesions, which could potentially show signs of progression during periods 
between relapses in MS. 
Most importantly, we found that anti-VAP-1 positivity of immunofluorescence 
data and ex vivo autoradiography of 68Ga-DOTA-Siglec-9 binding in fMOG-EAE 
was reduced 14 days after the inhibition of VAP-1 activity with LJP1586 indicating 
that 68Ga-DOTA-Siglec-9 is also capable of detecting the therapy effect of VAP-1 
targeting anti-inflammatory therapies. However, the autoradiography data at the 
acute phase revealed unexpected outcomes as 68Ga-DOTA-Siglec-9 binding 
increased for LJP1586 treated fMOG-EAE rats. In case of LJP1586, it is 
acknowledged that LJP1586 only inhibits enzymatic activity of VAP-1/SSAO 
(Stolen et al., 2005). Hence the binding of 68Ga-DOTA-Siglec-9 to its target, luminal 
VAP-1, could be independent of LJP1586 inhibitory activity at lest in the early 
phases of treatment, although lymphocyte infiltration to inflammation site has found 
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to be reduced. Another reason for this increased binding of 68Ga-DOTA-Siglec-9 
could be the ability of LJP1586 to alter the conformation of luminal VAP-1 during 
the treatment period. 
Interestingly, we found in the study I that the CNS lesion area expanded in 
LJP1586-treated rats at the remission phase, which might be explained by 
unfavorable timing of the VAP-1 inhibiting therapy. FMOG-EAE rats are designed 
to model acute widespread inflammation and cortical demyelination, which 
spontaneously recover over time and this acute pathogen-clearing inflammatory 
process should not be intervened (Merkler et al., 2006). On the other hand, the 
treatment of EAE in SJL mice with another SSAO/VAP-1 inhibitor, LJP1207, has 
mitigated the incidence and inhibited the development of clinical disability in EAE 
when the therapy was initiated after the first peak of the disease (O’Rourke et al., 
2007). This contradicts with the results observed in the study I with fMOG-EAE 
showing that the efficacy of SSAO/VAP-1 targeting therapy is dependent at least on 
the type of EAE model used and the onset of the intervention. As VAP-1 targeting 
therapies have these limitations in treating acute EAE and VAP-1 appeared to be 
upregulated rather in the hypercellular core of lesions than in microglia-rich NAWM 
around the inflammatory lesions, these limitations will also have negative influence 
on the potential of 68Ga-DOTA-Siglec-9 in monitoring lesion progression and 
inflammatory status in EAE. As activated microglia are believed to be the driving 
force behind ongoing demyelination in MS, but not necessarily in EAE, these 
features may potentially limit the clinical utility of 68Ga-DOTA-Siglec-9 for imaging 
MS patients. However, the clinical first-in-human studies with healthy individuals 
could aid in promoting the translation of 68Ga-DOTA-Siglec-9 PET imaging into 
clinical use. 
6.3 Evaluation of FR-β-targeted 18F-FOL for PET 
imaging of MS-like lesions 
In the study II, the prominent expression of FR-β during acute and chronic 
neuroinflammation in fDTH-EAE rat model provides a promising target for FR-
based molecular imaging agents, such as 18F-FOL, to monitor neuroinflammation. In 
addition, it has been confirmed that specific FR-targeting folate aminopterin 
therapies can modulate the course of the disease in EAE (Lu et al., 2014) indicating 
that FRs can play an important role in progression of the MS-like lesions and 18F-
FOL could be useful in evaluating this disease progression. When 18F-FOL was 
compared to the standard TSPO targeting tracer, 11C-PBR28, it could visualize both 
the acute and chronic phase inflammatory EAE lesions as could 11C-PBR28, but to 
the extent that 18F-FOL enabled the differentiation ex vivo between the acute 
inflammatory lesions and larger chronic inflammatory lesions with more severe 
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inflammation and lesion burden. This feature of 18F-FOL is largely contributed by 
the significantly lower background signal than current microglia and macrophage 
detecting TSPO targeting radiotracers including 11C-PBR28 has (Imaizumi et al., 
2008, Harberts et al., 2012, Datta et al., 2017). Another beneficial attribute in 18F-
FOL is the use of 18-fluorine label, which has shorter positron range than 11-carbon 
increasing the spatial resolution 18-fluorine can provide for PET images (Miller et 
al., 2010).  However, the 18F-FOL in vivo PET showed insufficient sensitivity in 
detecting the changes during lesion progression from the acute to chronic phase. 
Unfortunately, that was most likely due to too low spatial resolution (1.6mm3) of 
Inveon small animal PET camera (Goertzen et al., 2012) complicating the in vivo 
imaging of smaller acute lesions with average lesion size of approximately 0.06 mm2 
measured using histological evaluation. In the clinical setting, however, the median 
lesion size for MS patients is considered to be 30 – 40 mm2 in MRI considering that 
only 20% of brain lesions have nominal diameters less than 3.5 mm (Wang et al., 
1997 & Davis, 2013) With the performance of new digital PET/CT cameras, it is 
possible to acquire a spatial resolution of 2.7 mm3 indicating that these existing 
restrictions in pre-clinical PET imaging of focal EAE models might not apply with 
modern clinical PET imaging devices in patients with MS (Chicheportiche et al., 
2020). Therefore, 18F-FOL may overcome the observed limitations and it may 
support the translation of pre-clinical imaging protocols into clinical use. The ideal 
goal wth 18F-FOL would be to enable the detection of the lesion progression in vivo 
and identify the dominant polarization patterns of macrophages and microglia during 
CNS inflammation in MS 
According to the data obtained from the Study II, we found a positive correlation 
and co-localization of anti-MRC-1 and anti-FR-β positivity from correlation analysis 
and immunofluorescence stainings during the chronic phase of EAE. In addition, the 
anti-FR-β positivity correlated with decreased iNOS/MRC-1 –ratio as previously 
reported. On the other hand, anti-iNOS positivity showed weak correlation with FR-
β positivity. Previous studies are in line with our studies that 18F-FOL clearly binds 
more to MRC-1-positive macrophages than to iNOS-positive macrophages (Silvola 
et al., 2018) and FR-β expression is densest in areas of known ongoing remyelination 
and macrophage recruitment (Lassmann et al., 2007, Miron et al., 2013). Based on 
this assumption that MRC-1 expressing macrophages and microglia express more of 
FR-β than iNOS-expressing macrophages and microglia and anti-FR-β positivity is 
indicative for milder inflammation in EAE (Mikita et al., 2011), the FR-β targeting 
18F-FOL could potentially be used to evaluate the dominant polarization patterns of 
macrophages and microglia in vivo and predict the inflammation severity in the CNS 
lesions. Because MRC-1 positive (M2) phenotype is known to be associated with 
tissue remodeling and remyelination in MS (Miron et al., 2013, Nagai et al., 2006), 
one could suspect if 18F-FOL would have the potential to be utilized in in vivo 
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imaging of demyelination, remyelination and inflammation burden in MS. This 
could have implications in earlier identification of MS patients with increased risk 
of disease progression and inflammation severity, but limited potential in optimizing 
MS therapies as there are currently no approved therapies directly targeting 
demyelination or remyelination (U.S. Food and Drug Administration news release, 
2019). 
The 18F-FOL tracer uptake kinetics in the brain was successfully represented 
with kinetic Logan analysis for reversible binding rather than with kinetic Patlak 
analysis (data not shown) for irreversible binding. Based on previous studies on 
folate radioconjugates, the rate of tracer internalization could vary vastly among 
folate targeted tracers and disease models used (Muller et al., 2013). As FRs 
normally get internalized after binding to its ligand (Low et al., 2007) one would 
expect the irreversible portion of the 18F-FOL uptake to be significant in the brain, 
but instead the data obtained from Logan analysis showed significant reversible 
uptake of 18F-FOL. According to DVR and brain-to-blood values in Table 7, the 
uptake of 18F-FOL is still higher in the lesion side than in the contralateral side of 
the brain. It is known that distribution volume obtained from the graphical Logan 
analysis is independent of perfusion and should not influence to increased uptake in 
the lesion (Logan et al., 1990). Hence, this increased uptake may be due to increased 
binding of 18F-FOL to plasma proteins or transporters in close proximity of the lesion 
in the brain, which are unable to internalize the radiotracer. In addition, compromised 
BBB could possibly increase the distribution volume of 18F-FOL in fDTH-EAE rats. 
It must be taken into consideration that 18F-FOL is not FR-β specific and it can 
also bind to the other isoform of FR (FR-α) complicating the diagnostic in vivo PET 
imaging of FR-β positive MS-like inflammatory lesions. As FR-α is expressed in 
low concentrations in some structures of the brain (Low et al., 2007), the binding of 
the 18F-FOL could introduce bias in attempt to provide accurate information on FR-
β positive CNS lesions. 
Taken together, 18F-FOL could provide an alternative tool to acquire information 
with in vivo PET imaging on inflammatory status and lesion load in the brain during 
CNS inflammation and supplement with information that is not attainable using 
conventional TSPO-targeted PET. 
6.4 Evaluation of FR-β-targeted 68Ga-FOL for PET 
imaging of MS-like lesions 
In the Study III, we evaluated the effectiveness of FR-β targeted folate aminopterin 
conjugate EC2319 therapy in treating MS-like lesions in acute and chronic fDTH-
EAE and examined the utility of 68Ga-FOL to measure the therapy effect in fDTH-
EAE. Although EC2319 showed efficacy in reducing FR-β expression, lesion 
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volume and iNOS/MRC-1–ratio in chronic phase of inflammation, 68Ga-FOL 
showed insufficient signal-to-background ratio, sensitivity and binding to CNS 
inflammatory lesions both at acute and chronic phase of CNS inflammation to 
differentiate lesion progression and therapy efficacy between EC2319-treated and 
saline-treated lesions in vivo and ex vivo. However, the sensitivity of 68Ga-FOL was 
adequate enough to visualize the focal DTH-EAE lesions during the entire time 
course of the disease and to distinguish brain sections in vitro treated with EC2319 
at chronic phase of inflammation. In addition to the limitations observed with 18F-
FOL, the lack of sensitivity in detecting the treatment effect may results from the use 
of 68-gallium as a radiolabel for 68Ga-FOL radiotracer. 68Ga has larger positron range 
than commonly used 18F considerably reducing the spatial resolution than can be 
provided with 68Ga-FOL especially during small animal PET imaging when high 
resolution PET/CT cameras are used (Li & Conti, 2010). This is especially 
counterproductive if the relatively long positron range is combined with 1) the 
limited in vivo binding of 68Ga-FOL to FRs because of excessive plasma protein and 
transporter binding, and 2) the scarce overall availability of the target, FR-β, due to 
EC2319 therapy effect in the inflammatory brain lesions. 
The 1.6 mm3 spatial resolution of small animal Inveon multimodality PET/CT 
undoubtedly limits the in vivo detection of subtle changes in FR-β expression with 
68Ga-FOL (Goertzen et al., 2012). In the Study III, the lesion size was reduced by 
0.2 mm2 on average between EC2319-treated and saline-treated rats at chronic phase. 
In theory, this difference is very difficult to observe even if NOTA-Folate radiotracer 
would have been labeled with shorter positron range 18F in order to synthetize 18F-
FOL (Li & Conti, 2010). In addition, FRβ-expression was significantly reduced in 
the rats treated with EC2319 at chronic phase. This further reduces the availability 
of FR-β for 68Ga-FOL binding and complicates the detection of therapy effects and 
detection of the CNS lesion itself. 
Despite the drawbacks 68Ga-FOL arguably has compared to 18F-FOL, it still has 
potential to overcome the limitations traditional TSPO imaging possesses, such as, 
too high background, low receptor affinity, lack of selectivity towards macrophages 
and microglia and dependency for onsite cyclotron (Kreisl et al., 2010, Ching et al., 
2012, Aljammaz et al., 2014). 
The kinetic Logan analysis data for 68Ga-FOL in the Study III was in line with 
corresponding analysis performed with 18F-FOL in the Study II. The kinetic data 
obtained for 68Ga-FOL showed no differences in DVRLogan and in brain-to-blood 
ratios between 18F-FOL and 68Ga-FOL imaged fDTH-EAE rats (Table 7.). This 
indicates that 68Ga labeling of NOTA-Folate has minimal interference with tracer 
kinetics. However, the correlation data in table 7 showed very weak correlation 
between SUV–ratios and DVRLogan at acute phase of inflammation. This could be 
explained by both significantly lower lesions size of fDTH-EAE rats during acute 
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phase, which is limiting the capability of 68Ga-FOL to detect inflammatory lesions, 
and by lower spatial resolution in PET images caused by larger positron range in 
68Ga-FOL (Li & Conti, 2010). 
Regarding the clinical potential of 68Ga-FOL, it would be a tempting idea to use 
an optimal radiotracer in patients with MS that could evaluate lesion progression, 
inflammatory severity and predict disease progression without the need for onsite 
cyclotron (Aljammanz et al., 2014). However, the observed disadvantages of 68Ga-
FOL in this work have demonstrated that the individual benefit 68Ga-FOL may 
provide for in vivo PET imaging of MS patients is the independency from the 
cyclotron alone. 
6.5 Limitations of the studies 
These studies indicated that blocking of VAP-1/SSAO activity with small molecular 
inhibitor LJP1586 impaired the transmigration of lymphocytes into sites of 
inflammation in the brain during the acute inflammation in rats with fMOG-EAE. 
However, we have disregarded the role of soluble VAP-1 (sVAP-1) during the 
LJP1586 intervention. For example, it is known that the serum levels of sVAP-1 are 
increased in patients with active RRMS and absence of sVAP-1 in the CSF of RRMS 
patients indicate that soluble VAP-1 may be originated from its luminal form of 
VAP-1 (Airas et al., 2006). In addition, sVAP-1 levels might aid in regulation of 
VAP-1-dependent transmigration of leukocytes from bloodstream into site if 
inflammation without compromising the immunodefensive functions (Stolen et al., 
2005). The lack of sVAP-1 data in this work limits the evaluation of the role of 
sVAP-1 in regulating lymphocyte trafficking and LJP1586 therapy efficacy in EAE. 
Investigating the relationship between sVAP-1 and luminal VAP-1 in EAE would 
have provided valuable insights in regulatory roles of both forms of VAP-1 and 
possibly supported the translation of these findings to pathophysiology in human 
MS. Furthermore, it could have revealed mechanisms that possibly would have 
explained the efficacy or lack of efficacy of LJP1586 in treating CNS inflammation. 
Both of the EAE rat models used in the study I display some limitations when 
compared to conventional disseminated models of EAE (Svensson et al., 2002, 
Lyons et al., 1999). The fDTH-EAE and fMOG-EAE will form only an individual 
focal lesion whereas most EAE models will create new lesions in random and 
variable manner during the entire disease course. Therefore, fDTH-EAE and fMOG-
EAE models are not suitable for studying formation of new neighboring lesions, 
which is an essential component in MS (Waubant et al., 1997). Furthermore, the 
immunopathology of EAE lesions is typically dependent on the location of lesions, 
and on used animal, strain and antigen (Gold et al., 2006, Foster et al., 2008). For 
example, if EAE is induced in C57BL/6 mice using MOG-peptides in CFA for 
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immunization and pertussis toxin for activation of immune response, this will create 
a monophasic EAE without any relapses and CD4+ dominated inflammatory lesions 
prominently present in spinal cord (Steinman et al., 2006, Dal Canto et al., 1995). 
On the other hand, Swiss James Lambert mice immunized with MBP of MOG will 
establish a chronic relapsing-remitting EAE with active demyelination and 
inflammatory events in the brain (Mix et al., 2010). Furthermore, fDTH-EAE has 
shown lack of similarity for rarer pattern III and IV of demyelination in MS 
(Lucchinetti et al., 2005). In case of fDTH- and fMOG type EAE, the inflammatory 
cells mainly consist of CD8+ and macrophage dominant lesions with extensive 
remyelinating capacity after acute demyelination and antibodies involved in disease 
pathology of MOG induced EAE (Merkler et al., 2006, Serres et al., 2009). Certain 
types of MOG peptide fragments have implications to characteristic of the disease 
and to experimental designs that can be conducted (Lyons et al., 1999). In addition, 
the small size of the individual acute lesions in fDTH-EAE may exacerbate the 
limitations caused by the relatively low expression levels of molecular targets, such 
as VAP-1 and FR-β, available for PET imaging agents. Despite of vast amount of 
restrictions when creating an EAE model, we chose the most suitable models for our 
purpose to study the onset and development of EAE and to study the efficacy of 
novel therapeutics and utility of novel PET imaging agents in acute and chronic CNS 
inflammation (Anthony et al., 2014, Lyons et al., 2002). These models, however, 
require intracranial injection for the induction of the disease and the injection may 
cause inflammation at the injection site and possibly affect also the contralateral side 
of the brain. As non-operated healthy intact rats were only used in the study III, 
therefore, it can be regarded as a limitation in this work. 
The study results are also limited by lack of valid MRI data during the Study II 
and III, because due to random coil failures or malfunction in the clinical MRI 
device. High quality MRI would provide high resolution images, which could be 
used as anatomical reference for various areas of the brain supporting, validating or 
complementing the data acquired from PET imaging and aid in co-registration of 
PET and MR images. In addition, rat brain MR images can be used as a tool to 
evaluate BBB permeability during various stages of CNS inflammation and as an 
alternative method to demonstrate therapy effects of novel therapies (Jiang et al., 
2005). This would have been a robust method per se as it is currently used in clinical 
practices when evaluating therapies in patients with MS (Siffrin et al., 2010). 
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7 Conclusions 
The main goal of the thesis was to assess novel molecular imaging probes targeting 
alternative markers, FR and VAP-1, for in vivo PET imaging of neuroinflammation 
and EAE disease progression, respectively. In detail, we aimed to investigate the role 
of VAP-1 and FR-β in development of EAE lesions and the utility of VAP-1 targeted 
PET radiotracer, 68Ga-DOTA-Sigle-9, and the feasibility of FR-targeted radiotracers, 
18F-FOL and 68Ga-FOL, in monitoring CNS inflammation and progression of the 
disorder in EAE compared to second generation TSPO targeting radiotracer. In 
addition, we evaluated if VAP-1 and FR targeted PET probes enabled monitoring of 
the treatment efficacy in EAE rats. Finally, MRI, ex vivo autoradiography, 
immunofluorescence and immunohistochemistry were used to both acquire novel 
findings and confirm the findings obtained from in vivo PET imaging. According to 
the data shown in this thesis, the following conclusions can be drawn: 
1. 3T clinical MRI combined with rat-dedicated brain coil provides a 
feasible method for evaluating traditional CNS inflammatory lesions in 
rat models of MS without the use of high-resolution MRI. 
2. Luminal VAP-1 is involved in the development of acute MS-like lesions 
and remains to be expressed on lesion vasculature during remissions. 
68Ga-DOTA-Sigle-9 is capable of detecting neuroinflammation in the 
active MS-like lesions that present leukocyte infiltrates, but may not be 
suitable for evaluating new lesion formation and efficacy of therapies. 
3. FR-β is expressed on activated macrophages/microglia on EAE lesions 
and also in chronic MS lesions. FR targeting PET probe 18F-FOL can be 
used to assess EAE lesion development and acquire information that 
cannot be obtained with TSPO-targeted imaging. 
4. Novel folate aminopterin was effective only during chronic 
inflammation in EAE. 68Ga-FOL could visualize acute and chronic 
lesions, but lacked the ability to detect efficacy of therapies. FR-B may 
be a potential target for in vivo PET imaging of MS patients and 
development of novel therapeutics for MS patients. 
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